Table Of Content

Br J Clin Pharmacol 1995; 40: 603-610 AUTHOR INDEX (P = Proceedings) ABBOTT F. see MILLER RS. BACK D.J. see BARRY M.G. absorption of [14]C -coumarin in ABDELMAWLA A.H., LANGLEY BACK D.J. see GENTILE D.M. human skin, 196P R.W., SZABADI E. & BRADSHAW BACK D.J. see HOGGARD P.G. BEEDHAM C. see OLDFIELD S. C.M. Comparison of the effects of BACK D.J. see TOMLINSON ES. BELK D. see NOTARIANNI L.J. desipramine on noradrenaline-and BAILEY D.G., ARNOLD J.M.O., BELL D.R & JONES P.S Hepatic methoxamine-evoked BEND J.R., TRAN L.T. & SPENCE expression of mouse PPAR RNAs P, venoconstriction in man, 443 J.D. Grapefruit juice-felodipine 184 ABDULLAH I. see CLAPPERTON M. interaction: reproducibility and BELZ GG. see DE MEY C. AFFRIME M.B. see REIDENBERG P. characterization with the extended BEND J.R. see BAILEY D.G. AGOSTINIS L. see GARCIA- release drug formulation, 135 BENNETT P.N. see NOTARIANNI L.J. RODRIGUEZ L.A. BAILEY J.E. see COUPLAND N.J. BERDEAUxX A. see DURANTEAU J. AHONEN J., OLKKOLA K.T. & BALL D.E. & KAMALI F. Phenytoin BERGIN P. see GARDNER LB. NEUVONEN P.J. Effect of metabolism to 5 (4-hydroxy-phenyl)- BERNDT A., HOFFMAN C., itraconazole and terbinafine on the 5-phenylhydantoin in the cat is not RICHTER K., OERTEL R., pharmacokinetics and inhibited by sulphaphenazole, 183P VIERKANT A. & SIEGMUND W. pharmacodynamics of midazolam in BANFIELD C. see REIDENBERG P. Letter to the Editor: Tiracizine healthy volunteers, 270 BANMAIRUROI V. see disposition in healthy volunteers with AIACH M. see AZIZI M. AUPRAYOON P. reference to the debrisoquine AIRD S.A. see NOTARIANNI L.J. BANNWARTH B., LAPICQUE F., oxidation phenotype, 287 AKINYINKA 0.0. see SOWUNMI A. PEHOURCQ F., GILLET P., BESWICK P.H. see CLAPPERTON M. AL-SHIBANI N. & SKETT P. A change SCHAEVERBEKE T., LABORDE BHAGAT K., COLLIER J. & in the effect of guanamines on C., DEHAIS J..GAUCHER A. & VALLANCE P. Endotoxin-induced glycogen phosphorylase a activity in NETTER P. Stereoselective venous hyporesponsiveness in hepatocytes from streptozotocin disposition of ibuprofen enantiomers humans, 502P diabetic rats in different glucose in human cerebrospinal fluid, 266 BILLARD V., GAMBUS P.L., BARR J., concentrations, 185P BARBANOJ M.J. see AZCONA O. MINTO C-F., CORASH L., AL-SHIBANI N. & SKETT P. The effect BARBHATYA R.H. see DOCKENS R.C. TESSMAN J.W., STICKNEY J.L. & of guanamines (cyclised biguanides) BARBHATYA R.H., SHUKLA U.A. & SHAFER S.L. The pharmacokinetics on glycogen phosphorylase a activity GREENE D5. Lack of interaction of 8-methoxypsoralen following i.v. in hepatocytes from normal rats in between nefazodone and administration in humans, 347 different glucose concentrations, 185P cimetidine:steady state BILLAUD-MESGUISH E. see ALEXANDER §S.P.H. see COOPER J.A. pharmacokinetic study in humans, AZIZI M. ALHENC-GELAS M. see AZIZI M. 161 BIRKETT D.J. & McMANUS P. ALTYAR C.A. see DRAKE J. BARCELO S., GESCHER A. & Modelling the market uptake of new ALLEN A. see BULLIMAN S. CHIPMAN J.K. Sulphoraphane drugs following listing for subsidy in ALLOTT R.L. see HOWARD N.J. exhibits cytochrome Australia. A report from the Drug ALSPAC Survey Team see P4502E1-mediated activation of Utilisation Subcommittee of the HAWKINS N. dimethylnitrosamine, 193P Australian Pharmaceutical Benefits AMIN R. see SCHOORS D-F. BARHAM HLM. & STRATFORD Advisory Committee, 407 ANDREWS H.B. see BURKE J.G. IJ. Enzymology of the bioreduction BLAUW G.J.. WESTENDORP R.G,J., ARNOLD J.M.O. see BAILEY D.G. of the pyrazine mono-N-oxide SIMONS M., CHANG P.C., ARTHURS N. see HALL M. RB90740: roles for cytochrome P450 FROLICH M. & MEINDERS A.E. ASHTON C.H. see MOORE UJ. reductase and cytochrome b, release, Beta-adrenergic receptors contribute ASSENDELFT W.J.J. see LIJESEN 181P to hypoxaemia induced G.K.S BARHAM H.M., CHINJE E.C., vasodilatation in man, 453 ATKIN P.A. see SHENFIELD G.M. PATTERSON A. & STRATFORD BOGLE R.G. see DAVIES G. ATKINSON L. see GUPTA S.K. I.J. Toxicity of the bioreductive drug BOLDT J., MATTHIAS M., HEESEN AUPRAYOON P., SUKONTASON K., SR 4233 (tirapazamine) is determined M., HARTER K. & NA-BANGCHANG K., by P450 reductase activity in human HEMPELMANN G. BANMAIRUROI V., MOLUNTO P. breast but not lung cancer lines, 194P Cardiorespiratory effects of & KARBWANG J. Pharmacokinetics BARR J. see BILLARD V. continuous i.v administration of the of quinine in chronic liver disease, 494 BARRY M.G. see HOGGARD P.G. ACE inhibitor enalaprilat in the AZCONA O., BARBANOJ M.J., BARRY M.G., BACK D.J. & critically ill, 415 TORRENT J. & JANE F. Evaluation BRECKENRIDGE A.M. Zidovudine BONN R. see CAWELLO W. of the central effects of alcohol and therapy in HIV infection: which BOON N.A. see NEWBY D.E. caffeine interaction, 393 patients should be treated and when, BRADBURY A. see WORBOYS P.D. AZIZI M., VEYSSIER-BELOT C., 107 BRADSHAW C.M. see ALHENC-GELAS M., BARRY P.W. & O’CALLAGHAN C. ABDELMAWLA A.H. CHATELLIER G., BILLAUD- The effect of delay, multiple BRECKENRIDGE A. The Lilly Lecture, MESGUISH E., FIESSINGER J.N. actuations and spacer static charge on 1994: Science, medicine and clinical & AIACH M. Comparison of the in vitro delivery of budesonide pharmacology, | biological activities of two low from the Nebuhaler, 76 BRECKENRIDGE A.M. see BARRY molecular weight heparins in 10 BECKLEY-KARTEY S.A.J. & MG. healthy volunteers, 577 HOTCHKISS S.A.M. Topical in vitro BRENNAN BS. see CARLILE D.J. © 1995 Blackwell Science Ltd 603 604 Index BRES J. see HILLAIRE-BUYS D. CHINJE E.C. see BARHAM H.M. DALEY-YATES P.T. see McCAPPIN BRETT S.E. see COCKCROFT J.R. CHIPMAN J.K. see BARCELO S. T.R. BRITTON J. see HILL J. CHIPMAN J.K., DAVIES J.E., DASH DARGIE H.J. see CLAPPERTON M. BRODDE O.-E. see SCHAFERS R.F. P. & DOEHMER J. Use of the DASH P. see CHIPMAN J.K. BROWN M.J. see FERRO A. Comet assay to detect activation of, DAUL A.E. see SCHAFERS RF. BRUNE K. see GEISSLINGER G. 2-amino-3methylimidazo (4,5-f) DAVEY P. see WALLEY T. BRUNE K. see LOTSCH J. quinoline (IQ) in V79 cells expressing DAVIDSON C. see IVERSEN S.A. BULLIMAN S., ALLEN A., HARRIS CYP1A2 and acetyltransferase, 193P DAVIDSON D. see IVERSEN S.A. A.M., WRITER D.J., FREED ML, CHOWIENCZYK PJ. see DAVIES C.D. see HOWARD N.J. DICICCO R., ZARIFFA N. & COCKCROFT JR. DAVIES G., MacALLISTER R.J., JORKASKY D.K. The influence of CLAPPERTON M., BESWICK P.H., BOGLE R.G. & VALLANCE P. food on the pharmacokinetics of BRL ABDULLAH L., DARGIE H.J., Effect of diadenosine phosphates on 49653C in healthy male volunteers, FISHER A.C. & McMURRAY human umbilical vessels: novel 517P J. Effect of captopril, enalaprilat and platelet-derived vasoconstrictors, 170 BULLMAN J. see COMPTON C. mercaptopropionyl glycine (MPG) on DAVIES J.E. see CHIPMAN J.K. BURKE J.G., DURSUN S.M., the oxidative activity of human DAVIES J.G., PHILLIPS G.J., OLLIFF REVELEY M.A. & ANDREWS H.B. isolated neutrophils, 31 C.J., STREET M. & KINGSWOOD Effects of sulpiride on voluntary CLARKE H. see RASHID T.J. C. A comparison of cefpirome saccadic eye movements (VSEMs) in CLARKE S.E. see OLDFIELD S. clearance by in vitro models of schizophrenia, 515P CLARKSON P.B.M., LIM P.O. & haemofiltration and haemodialysis, 521 BURKE M_D see EKINS S. MacDONALD T.M. Influence of DE ABAJO F. see MARTIN ARIAS L.H. BUTZER R. see DE MEY C. basal nitric oxide secretion on cardiac de BELDER A. see RAMSAY B. BYE A. see MACKIE AE. function in man, 307 DE GROOT R. see WALKER D.K. COCKCROFT J.R., CHOWIENCZYK DE MEY C., SCHROETER V., CABANIS M.J. see ROSENZWEIG P. P.J., BRETT S.E., MANT T.G.K., BUTZER R., ROLL S. & BELZ G.G. CALDWELL J. see GARDNER LB. DURNIN C., LYNN F., Method specificity of non-invasive CAPLAIN H. see ROSENZWEIG P. STEVENSON P. & RITTER J.M. blood pressure measurement: CARGILL R.I. & LIPWORTH The effect of HN-65021 on responses oscillometry and finger pulse pressure B.J. Acute effects of ANP and BNP to angiotensin II in human forearm vs acoustic methods, 291 on hypoxic pulmonary vasculature, 591 DE MEYER G. see DE SMET M. vasoconstriction in humans, 585 COLEMAN T., LENNARD MSS. & DE NUCCI G. see MUSCARA M.N. CARGILL R.I. & LIPWORTH B.J. The TUCKER G.T. Metabolism of the DE SMET M. see SCHOORS D-F. role of the renin-angiotensin and CYP2D substrates metoprolol and DE SMET M., SCHOORS D.F., DE natriuretic peptide systems in the bufuralol by rat brain and liver MEYER G., VERBESSELT R., pulmonary vasculature, 11 microsomes, 189P GOLDBERG M.R. & CARGILL R.I. see KIELY D.G. COLLIER J. see BHAGAT K. FITZPATRICK V. Effect of multiple CARGILL R.I. see TAN K:S. COLUCCI R. see REIDENBERG P. doses of losartan on the CARLILE D.J.. BRENNAN B5., COMPTON C., BULLMAN J., DOYLE pharmacokinetics of single doses of ZOMORODI K. & HOUSTON J.B. E., DURIE S., GEORGIOU P., digoxin in healthy volunteers, 571 Induction of diazepam clearance in HIGGINS R., UPWARD J. & KAYE DEARDEN J.C. see MAHMUD R. vitro in rat by dexamethasone: C. The pharmacokinetics of oral BRL DEGNER F.L., HEINZEL G., NARJES quantitative predictions from 55834 in healthy male subjects, 518 P H. & TURCK D. The effect of microsomal and hepatocyte studies, COOPER J.A., HILL S.J, meloxicam on the pharmacokinetics 18iP ALEXANDER §.P.H., RUBIN P.C. of beta-acetyl-digoxin, 486 CARROLL K. see DONAVAN A.J.G. & HORN E.H. Adenosine receptor- DEHAIS J. see BANNWARTH B. CARVAJAL A. see MARTIN ARIAS induced cyclic AMP generation and DEMNATI R., MICHOUD M.C., L.H. inhibition of 5-hydroxytryptamine JEANNERET-GROSJEAN A. & CATALIN J. see SAMPOL E. release in human platelets, 43 DU SOUICH P. Plasma CATTARUZZI C. see GARCIA- COPE L. see WYNNE H. concentrations and effects of RODRIGUEZ L.A. CORASH L. see BILLARD V. salbutamol administered orally to CAWELLO W., LEONHARDT A., COUPLAND N.J., BAILEY J.E., GLUE patients with cystic fibrosis, 319 SCHWEER H., SEYBERTH H.W., P. & NUTT D.J. The cardiovascular DESAI N. see OO CY. BONN R. & LOMELI A.L. Dose and subjective effects of thyrotropin DESPAUX E. see HILLAIRE-BUYS D. proportional pharmacokinetics of releasing hormone (TRH) and a DICICCO R. see BULLIMAN S. alprostadil (prostaglandin E1) in stable analogue, dimethyl proline- DINGEMANSE J., JORG K., healthy volunteers following TRH, in healthy volunteers, 223 ZURCHER G., SCHMITT M., intravenous infusion, 273 COVILLE P-F. see SEDEK G., DA PRADA M. & VAN CHADWICK LG. see YEO W.W. WANWIMOLRUK S. BRUMMELEN P. Pharmacokinetic- CHANG P.C. see BLAUW G.J. CRAWFORD D., MADDOCKS J.L., pharmacodynamic interaction CHARLETT A. see PURKISS A.G. JONES D. & SZAWLOSKI P. between the COMT inhibitor CHATELLIER G. see AZIZI M. Rational design of tolcapone and single-dose levodopa, CHAUFOUR S. see ROSENZWEIG P. immunosupressants: thioethers- 253 CHEN C.-S. see CHEN C.-Y. azothioprine analogues without bone DJAVANMARD M.P. see MADER CHEN C.-Y. & CHEN C--S. marrow toxicity, 507P R.M. Stereoselective disposition of CRAWFORD FE. see DRAKE J. DOBBS R.J. see PURKISS A.G. ibuprofen in patients with CRONIN M.T.D. see MAHMUD R. DOBBS S.M. see PURKISS A.G. compromised renal haemodynamics, CURSON V.H. see FAIRWEATHER DOCKENS R.C., RAPOPORT D., 67 D.B. ROBERTS D., GREENE D.D. & CHENG H. see SCHOORS D.F. BARBHATYA R.H. Lack of an effect CHIBA K. see KOBAYASHI K. DA PRADA M. see DINGEMANSE J. of nefazodone on the CHING D. see PURKISS A.G. DAHL M. see KIIVET R.A. pharmacokinetics and © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 605 pharmacodynamics of theophylline DUNMORE C., DUBRUC C. & GIFFORD L.A. see WITHEROW L.E. during concurrent administration in HINDMARCH I. The psychomotor GILL H.J., TINGLE M.D. & PARK patients with chronic obstructive and cognitive effects of litoxetine in B.K. Metabolism of dapsone by pulmonary diseases, 598 young and middle aged volunteers, multiple isoforms of human DOEHMER J. see CHIPMAN J.K. 119 cytochrome P450, 510P DONAVAN A.J.G., WILLIAMS A.J., FEELY J. see HALL M. GILL H.J., TINGLE M.D. & PARK K. CARROLL K. & TUERSLEY M.D. FEHER M.D., SIMMS J.P. & LANT N-Hydroxylation of dapsone by Specificity of heart rate reduction by A.F. Steroid cards, chicken pox and multiple enzymes of cytochrome ZD7288, a sino atrial node doctor/patient communication, 513P P450: implications for inhibition of modulator, as assessed by FERRAZ J.G. see MUSCARA MLN. haemotoxicity, 531 transthoracic electrical bioimpedance FERRO A., LONGMORE J., HILL GILLET P. see BANNWARTH B. (TEB) during exercise in healthy R.G. & BROWN M.J. A comparison GIUDICELLI J. see DURANTEAU J. males, 514P of the contractile effects of 5-hydroxy- GLUE P. see COUPLAND N.J. DONNELLY R. see PANFILOV V. tryptamine, sumitriptan and MK-462 GLUE P. see REIDENBERG P. DOYLE E. see COMPTON C. on human coronary artery in vitro, GOLDBERG M.R. see DE SMET M. DRAKE J., ALITYAR C.A., 245 GOLDING J. see HAWKINS N. KIRK PATRICK C.T., CRAWFORD FERRO CJ. see WEBB D.J. GOLDSTEIN DSS. see EISENHOFER F.E., GIBSON P. & HORTH C.E. FIEGER H. see DUCHARME J. G. Effects of food on the FIESSINGER J.N. see AZIZI M. GORCHEIN A. Letter to the Editor: pharmacokinetics of two controlled FISHER A.C. see CLAPPERTON M. Treatment of Parkinson’s disease in a release oral morphine formulations, FITZPATRICK V. see DE SMET M. patient with acute intermittent oramorph SR and MST continus, FLORIN S. see LOTSCH J. porphyria, 105 517P FRASER A.G., ROASALKI S.B., GRAHAM S.G. see TATEISHI T. DU SOUICH P. see DEMNATI R. GAMBLE G.D. & POUNDER RE. GRANDE L., LACIMA G., PEREZ A. DUBRUC C. see FAIRWEATHER D.B. Inter-individual and intra-individual & ZAYAS J.M. Lack of effect ofa DUCHARME J., FIEGER H., variability of ethanol concentration- 5-HT3 antagonist, pancopride, on DUCHARME M.P., KHALIL time profiles: comparison of ethanol lower oesophageal sphincter pressure S.K.W. & WAINER LW. ingestion before or after an evening in volunteers, 401 Enantioselective disposition of meal, 387 GRANT M.H. see WILSON Y hydroxychloroquine after a single oral FREED M.I. see BULLIMAN S. GRAY A.J. see NEWBY D.E. dose of the racemate to healthy FRIBERG P. see EISENHOFER G. GRAZIA TRONCON M. see GARCIA- volunteers, 127 FRIEDMAN BSS. see UEMATSU T. RODRIGUEZ L.A. DUCHARME M.P. see DUCHARME J. FROLICH M. see BLAUW G.J. GREENE D.D. see DOCKENS R.C. DUNMORE C. see FAIRWEATHER GREENE DS. see BARBHATYA R.H. D.B. GALTEAU M.M. see PANSERAT S. GROVE A. see TAN K:.S. DURAND A. see SAMPOL E. GAMBLE G_D. see FRASER A.G. GUILLAUME M. see REIDENBERG DURANTEAU J., PUSSARD E., GAMBUS P.L. see BILLARD V. Pp. BERDEAUX A. & GIUDICELLI GARCIA-RODRIGUEZ L.A., GUNRAJ P.E. see WIEBKIN P-F. J. Effects of the angiotensin type 1 CATTARUZZI C., GRAZIA GUPTA S.K., ATKINSON L., TU T. & receptor antagonist, losartan, on TRONCON M., AGOSTINIS L. & LONGSTRETH J.A. Age and gender systemic and regional vascular SIMON G. Letter to the Editor: related changes in stereoselective responses to lower body negative Acute liver injury and droxicam use in pharmacokinetics and pressure in healthy volunteers, 431 DURIE S. see COMPTON C. the region of Friuli-Venezia Giulia, pharmacodynamics of verapamil and 104 norverapamil, 325 DURNIN C. see COCKCROFT JR. DURSUN S.M. see BURKE J.G. GARDNER LB., BERGIN P., GUY S. see THAM T.C.K. STENING P., KENNA J.G. & EDWARDS C. see WYNNE H. CALDWELL J. Immunochemical HALL M., McCORMAC P., ARTHURS EICHELBAUM M. see KIVISTO K.T. detection of covalently modified N. & FEELY J. The spontaneous EISENHOFER G., FRIBERG P., hepatic proteins produced following reporting of adverse drug reactions by GOLDSTEIN DS. & ESLER M. administration of methyleugenol to nurses, 173 Differential actions of desipramine on rats, 196P HALLIDAY R.C., JONES B.C., SMITH sympathoadrenal release of GAUCHER A. see BANNWARTH B. D.A. & PARK B.K. Halofantrine is a noradrenaline and adrenaline, 263 GAZZARD B.G. see substitute of cytochrome P4503A EKINS S., MURRAY G.L, BURKE NOORMOHAMED F.H. (CYP3A), 195P M.D, MARCHANT N.M. & GEISSLINGER G. see LOTSCH J. HALLIDAY R.C., JONES B.C., SMITH HAWKSWORTH G.M. Epoxidation, GEISSLINGER G., MENZEL S., D.A. & PARK B.K. Structural diol formation and glutathione WISSEL K. & BRUNE K. requirements for the inhibition of conjugation in rat hepatocytes and Pharmacokinetics of ketoprofen CYP2D6 by imipramine, 194P precision-cut liver slices, 180P enantiomers after different doses of HALLIDAY R.C., JONES B.C., SMITH EKLUNDH T. see KIIVET R.A. the racemate, 73 D.A., KITTERINGHAM N.R. & ELLIS S.W., HAYHURST G_P., GENTILE D.M. & BACK PARK B.K An investigation of the HARLOW J.R., LENNARD MS., D.J. Inhibition of dexamethasone interaction between halofantrine, TUCKER G.T., SIMULA A.P., 6-hydroxylation in human liver CYP2D6 and CY P3A¢4: studies with SMITH G. & WOLF C.R. Catalytic microsomes, 192P human liver microsomes and functions of aspartic acid 301 in GEORGE C.F. see RASHID T.J. heterologous enzyme expression debrisoquine, 4-hydroxylase GEORGIOU P. see COMPTON C. systems, 369 cytochrome P450 (CYP2D6), 178P GERARD N. see PANSERAT S. HARA K. see UEMATSU T. ESLER M. see EISENHOFER G. GERSLINGER G. see LOTSCH J. HARLOW JR. see ELLIS S.W. GESCHER A. see BARCELO S. HARRIS A.M. see BULLIMAN S. FAIRWEATHER D.B., PATAT A., GIBSON J. see STARMER G.A. HARTER K. see BOLDT J. ROSENZWEIG P., CURSON V.H., GIBSON P. see DRAKE J. HAWKINS N., GOLDING J. & © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 606 Index ALSPAC Survey Team. A survey of IND P.W. see HIGHAM M.A. KITTERINGHAM N.R. see HOWARD the administration of drugs to young IND P.W. see SHARAHA A.M. NJ. infants, 79 IND P.W. see SHARARA A.M. KITTERINGHAM N.R., KENNA J.G. HAWKSWORTH G.M. see EKINS S. IREDALE M.J. see SHARARA A.M. & PARK B.K. Detection of HAYHURST G_P. see ELLIS S.W. ISHIZAKI T. see KOBAYASHI K. autoantibodies directed against HAYNER W.G., MOFFAT S. & WEBB IVERSEN S.A., DAVIDSON D. & human hepatic endoplasmic reticulum D.J. An investigation into the direct DAVIDSON C. The acceptability of in sera from patients with halothane- and indirect venoconstrictor effects of resin therapy to patients attending a associated hepatitis, 379 endothelin-1 and big endothelin-1 in hospital lipid clinic, 92 KIVISTO K.T., KROEMER H.K. &' man, 307 EICHELBAUM M. The role of HAYNES W.G. see STRACHAN F-.E. JACKSON P.R. see ROSTAMI- human cytochrome P450 enzymes in HAYNES W.G. see WEBB D.J. HODJEGAN A. the metabolism of anticancer agents: HEESEN M. see BOLDT J. JACKSON P.R. see YEO W.W. implications for drug interactions, 523 HEINZEL G. see DEGNER F.L. JACQZ-AIGRAIN E. see PANSERAT S. KNIGHTS K.M., McLEAN CLF., HEMPELMANN G. see BOLDT J. JAKESZ R. see MADER R.M. TONKIN A.L. & MINERS J.O. HENRY J.A. see MINTON N.A. JANE F. see AZCONA O. Lack of effect of gender and oral HIGGINS R. see COMPTON C. JEANNERET-GROSJEAN A. see contraceptive steroids on the HIGHAM M.A. see SHARAHA A.M. DEMNATIR. pharmacokinetics of (R)-ibuprofen in HIGHAM M.A., SHARARA A.M., JOEL S.P. see THOMPSON PI. humans, 153 MAGEE R.P. & IND P.W. JOHN L. see THOMPSON P.I. KOBAL G. see LOTSCH J. Determination of the minimum dose JONES B. see HYLAND R. KOBAYASHI K., YAMAMOTO T., of lactose drug carrier that can be JONES B.C. see HALLIDAY R.C. CHIBA K., TANI M., ISHIZAKI T. sensed during inhalation, 281 JONES D. see CRAWFORD D. & KUROIWA Y. The effects of HILL J. & BRITTON J. Dose-response JONES P.S see BELL D.R selective serotonin reuptake inhibitors JORG K. see DINGEMANSE J. relationship and time-course of the and their metabolites on JORKASKY D.K. see BULLIMAN S. effect of inhaled magnesium sulphate S-mephenytoin, 4-hydroxylase on airflow in normal and asthmatic activity in human liver microsomes, KAMALIF. see BALL DE. 481 subjects, 539 KAMALI F. see WYNNE H. HILL R.G. see FERRO A. KOSUGE K. see UEMATSU T. KAMALI F., HOWES A., THOMAS HILL S.J. see COOPER J.A. S.H.L. & SNOECK E. The effects of KRASKIEWICZ M. see YEO W.W. HILLAIRE-BUYS D., PEYRIERE H., ranitidine and cimetidine on the KRISHNAMOORTHY R. see LOBJOIE E., BRES J., OSSART M. pharmacokinetics and PANSERAT S. & DESPAUX E. Influence of arterio- pharmacodynamics of nebivol P, 519 KRIVORUK Y. see TATEISHI T. KROEMER HK. see KIVISTO K.T. venous haemofiltration on teicoplanin KANAMARU M. see UEMATSU T. elimination, 95 KANG W. see WANWIMOLRUK S. KUHN RJ. seeOO C.Y. KUROIWA Y. see KOBAYASHI K. HINDMARCH I. see FAIRWEATHER KARBWANG J. see AUPRAYOON P. KVISTO K.T., KROEMER H.LK. & D.B. KAYE C. see COMPTON C. HOFFMAN C. see BERNDT A. KELLY P. see WYNNE H. EICHELBAUM M. Review. The role of human cytochrome P450 enzymes HOFSTATTER E. see MUSCARA M.N. KENNA J.G. see GARDNER LB. in the metabolism of anticancer HOGGARD P.G., VEAL G.J., BARRY KENNA J.G. see KITTERINGHAM agents: implications for drug M.G. & BACK D.J. Zidovudine N.R. interactions, 259 phosphorylation in peripheral blood KHALIL S.K.W. see DUCHARME J. mononuclear cells in vitro: effect of KHAN S. & SKETT P. The effect of LABORDE C. see BANNWARTH B. depleting T4 cells P, 191 DMSO on steroid metabolism in LACARELLE B. see SAMPOL E. HOP W.C.J. see VAN DEN ANKER cultured rat hepatocytes in the LACIMA G. see GRANDE L. JN. presence of hydrocortisone and LANGLEY R.W. see ABDELMAWLA HORN E.H. see COOPER J.A. insulin P, 186 HOROWITZ J.D. see ZHANG Y. KIELY D.G., CARGILL RI. & A.H. LANT A.F. see FEHER M.D. HORTH C.E. see DRAKE J. LIPWORTH B.J. Angiotensin II HOTCHKISS S.A.M. see BECKLEY- blockade attenuates hypoxic LANT A.F. see NOORMOHAMED KARTEY S.A.J. pulmonary vasoconstriction in man, F.H. 505P LAPICQUE F. see BANNWARTH B. HOUSTON J.B. see CARLILE D.J. KIELY D.G., CARGILL RI. & LARSON P. see SCHOORS D.F. HOUSTON J.B. see WITHEROW L.E. LIPWORTH B.J. Cardiopulmonary LEE MLR. see NEWBY D.E. HOUSTON J.B. see WORBOYS P.D. interactions of salbutamol and LEITCH A. see SILKE B. HOWARD N.J., DAVIES C.D., hypoxaemia in healthy young LEITE G. see MUSCARA MLN. ALLOTT R.L., MADDEN S., volunteers, 313 LENNARD L. see ROSTAMI- PIRMOHAMED M., KIELY D.G., CARGILL RI. & HODJEGAN A. KITTERINGHAM N.R. & PARK LIPWORTH B.J. Cardiopulmonary LENNARD M.S. see COLEMAN T. B.K. Species variation in microsomal interactions of salbutamol and LENNARD M.S. see ELLIS S.W. epoxide hydrolase activity, 509P hypoxaemia P, 506 LEONARDI S. see MUSCARA MLN. HOWES A. see KAMALI F. KITVET R.A., LLERENA A., DAHL M., LEONHARDT A. see CAWELLO W. HUMMEL T. see LOTSCH J. ROOTSLANE L., VEGA JS., LIJESEN G.K.S, THEEUWEN L, HUSSEIN Z. see LIPTROT J. EKLUNDHT. & SJOQVIST F. ASSENDELFT W.J.J. & VAN DER HUTCHEON LG. see STRACHAN Patterns of drug treatment of WAL G. The effect of human FE. schizophrenic patients in Estonia, chorionic gonadotropin (HCG) in the HYLAND R., JONES B., LOGAN A., Spain and Sweden, 467 treatment of obesity by means of the MANSFIELD R., MOORE R. & KINGSWOOD C. see DAVIES J.G. Simeons therapy: a criteria-based SMITH D. Production of a human KIRKPATRICK C.T. see DRAKE J. meta-analysis, 237 CYP3A antibody from multiple KITTERINGHAM NR. see LILLEYMAN JS. see ROSTAMI- peptide sequences, 179P HALLIDAY R.C. HODJEGAN A. © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 607 LIM J. see REIDENBERG P. MARSH V.R see MOORE U.J. HOFSTATTER E., LEITE G., LIM P.O. see CLARKSON P.B.M. MARTIN ARIAS L.H., CARVAJAL A., MAGALHAES A.F., LEONARDI S. LIN C. see REIDENBERG P. MARTIN DE DIEGO IL. & DE & DE NUCCIG. Plasma hydroxy- LIPTROT J., MERCER J., HUSSEIN ABAJO F. Letter to the Editor: metronidazole/metronidazole ratio in Z., SEABER E. & POSNER J. The Before and after triazolam:changes in patients with liver disease and in tolerability and pharmacokinetics of the consumption of hypnotics in healthy volunteers, 477 loading and maintenance intravenous Spain, 289 infusions of 619C89 in healthy MARTIN DE DIEGO I. see MARTIN NA-BANGCHANG K. see volunteers, 507P ARIAS L.H. AUPRAYOON P. LIPWORTH B.J. see CARGILL R.I. MARTIN J.F. see RAMSAY B. NAISBITT D.J., WILLIAMS D.P., LIPWORTH B.J. see KIELY D.G. MARTIN U. see RASHID T.J. PIRMOHAMED M., O’NEILL LIPWORTH B.J. see TAN KS. MARTIN-MUNLEY S. see P.M., PIRMOHAMED M., LLERENA A. see KITVET R.A. NOORMOHAMED F.H. O’NEILL P.M. & PARK B.K. LOBJOIE E. see HILLAIRE-BUYS D. MASCORD D.J. see STARMER G.A. Depletion of intracellular glutathione LOGAN A. see HYLAND R. MATAS N., THYGESEN P. & SIM E. in polymorphonuclear leucocytes by LOMAX C.C. see STRACHAN F-.E. Molecular genetics of human antimalarial drugs, 511P LOMELI A.L. see CAWELLO W. arylamine n-acetyltransferase: NAKASHIMA M. see UEMATSU T. LONGMORE J. see FERRO A. physical mapping, 522P NARJES H. see DEGNER F.L. LONGSTRETH J.A. see GUPTA S.K. MATTHIAS M. see BOLDT J. NEIJENS H.J. see WALKER D.K. LOPEZ-JARAMILLO P. see MATTILA M.J. see VANAKOSKI J. NETTER P. see BANNWARTH B. RAMSAY B. McCAPPIN T.R. & DALEY-YATES NEUVONEN PJ. see AHONEN J. LOTSCH J., GERSLINGER G., P.T. The pharmacokinetics and NEWBY D.E., LEE M.R., GRAY AJ. & MOHAMMADIAN P., BRUNE K. pharmacodynamics of BOON N.A. Letter to the Editor: & KOBAL G. Effects of flurbiprofen bisphosphonates in rats with retinoid- Enalapril overdose and the corrective enantiomers on pain-related induced bone resorption, 183P effect of intravenous angiotensin II, chemosomato-sensory evoked McCORMAC P. see HALL M. 103 potentials in human subjects, 339 McDERMOTT B.J. see THAM T.C.K. NICHOLLS M.G. see WOO K:S. LOTSCH J.,. MOHAMMADIAN P., McFARLANE L.C. see TAN K:S. NOMEIR A. see REIDENBERG P. HUMMEL T., FLORIN S., McLEAN C.F. see KNIGHTS K.M. NOORMOHAMED F.H., YOULE BRUNE K., GEISSLINGER G. & McLEAN S. see MILLER RS. M.S., TANG B., MARTIN- KOBAL G. Effects of azapropazone McMANUS P. see BIRKETT D.J. MUNLEY S., GAZZARD B.G. & on pain-related brain activity in McMURRAY J. see CLAPPERTON M. LANT A-F. Foscarnet-induced human subjects, 545 McNAMARA P.J. see OO C.Y. changes in plasma calcium and LYLES G.A. see PINO R. MEEHAN J. see REIDENBERG P. magnesuim in HIV seropositive LYNN F. see COCKCROFT J.R. MEINDERS AE. see BLAUW G.J. patients, 502P MENZEL S. see GEISSLINGER G. NOTARIANNI L.J., BELK D., AIRD MacALLISTER R.J. see DAVIES G. MERCER J. see LIPTROT J. S.A. & BENNETT P.N. An in vitro MacDONALD T.M. see CLARKSON MICHAEL-TITUS A.T., WHELPTON technique for the rapid determination P.B.M. R. & YAQUB Z. Binding of of drug entry into breast milk, 333 MACKIE A.E., VENTRESCA G_P., temoporfin to the lipoprotein NURMINEN S. see ROSTAMI- MOSS J.A. & BYE A. fractions of human serum, 594 HODJEGAN A. Pharmacokinetics of intravenous MICHOUD M.C. see DEMNATI R. NUTT DJ. see COUPLAND N.J. fluticasone propionate in healthy MILLER R.S., PETERSON G.M., subjects, 198P ABBOTT F., MADDOCKS L, O’CALLAGHAN C. see BARRY P.W. MACKLIN BS. see ROBERTS J. PARKER D. & McLEAN S. Plasma O’KANE K.P.J. see STRACHAN F-.E. MACLEAN M. see THOMPSON PI. concentrations of fentanyl with O’NEILL C.J.A. see PURKISS A.G. MADDEN S. see HOWARD N.J. subcutaneous infusion in palliative O’NEILL P.M. see NAISBITT D.J. MADDOCKS I. see MILLER RS. care patients, 553 O’SHEA N. see ROBERTS J. MADDOCKS J.L. see CRAWFORD D. MINERS J.O. see KNIGHTS K.M. OERTEL R. see BERNDT A. MADER R.M., STEGER G.G., MINTO C.F. see BILLARD V. OLDFIELD S., CLARKE S.E. & RIZOVSKI B., DJIAVANMARD MINTON N.A., TURNER J. & HENRY BEEDHAM C. In vitro interaction of M.P., SCHEITHAUER W., JAKESZ J.A. Pharmacodynamic and (E)-5-(2-bromoviny] )uracil with, R. & RAINER H. Stereospecific pharmacokinetic interactions between 5-fluorouracil metabolism in human pharmacokinetics of rac-5- theophylline and propranolol during liver, 189P methyltetrahydrofolic acid in patients dynamic exercise, 521P OLKKOLA K.T. see AHONEN J. with advanced colorectal cancer, 209 MIRANDA E.L. see MUSCARA M.N. OLLIFF C.J. see DAVIES J.G. MAGALHAES A.F. see MUSCARA MOFFAT S. see HAYNER W.G. OO C.Y., KUHN R.J., DESAI N., MLN. MOHAMMADIAN P. see LOTSCH J. WRIGHT C.E. & MCNAMARA MAGEE R.P. see HIGHAM M.A. MOLUNTO P. see AUPRAYOON P. P.J. Pharmacokinetics in lactating MAGGS J.L. see TOMLINSON ES. MOORE R. see HYLAND R. women: prediction of alprazolam MAGGS J.L. see WILLIAMS D. MOORE U.J., MARSH V.R, ASHTON transfer into milk, 231 MAHMUD R., TINGLE M_D., C.H. & SEYMOUR R.A. Effects of OSSART M. see HILLAIRE-BUYS D. CRONIN M.T.D., DEARDEN J.C. peripherally and centrally acting & PARK B.K. The chemical basis of analgesics on somatosensory evoked PAGE K.M. see WIEBKIN P.F. dapsone haemotoxicity, 511P potentials, 111 PANFILOV V., MORRIS A.D., MALLETT C.D. see WIEBKIN P.F. MORRIS A.D. see PANFILOV V. DONNELLY R., SCEMAMA M. & MANSFIELD R. see HYLAND R. MOSS J.A. see MACKIE A.E. REID J.L. The effects of rilmenidine MANT T.G.K. see COCKCROFT J.R. MURA C. see PANSERAT S. and atenolol on mental stress, MARCHANT N.M. see EKINS S. MURRAY GLI. see EKINS S. dynamic exercise and autonomic MARGOLSKEE D. see SCHOORS MUSCARA M.N., PEDRAZZOLI Jr J., function in mild to moderate DF. MIRANDA E.L., FERRAZ J.G., hypertension, 563 © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 608 Index PANSERAT S., MURA C., GERARD the absolute bioavailability of A.E., PHILIPP TH. & BRODDE N., VINCENT-VIRY M., GALTEAU nifedipine, 51 O.-E. Influence of adrenergic and M.M., JACQZ-AIGRAIN E. & REID J.L. see PANFILOV V. mucarinic receptor blockade on the KRISHNAMOORTHY R. An REIDENBERG P., GLUE P., cardiovascular in vivo effects of unequal cross-over event within the BANFIELD C., COLUCCI R., exogenously administered and CYP2D gene cluster generates a MEEHAN J., REY E., endogenously released noradrenaline chimeric CYP2D7/CYP2D6 gene RADWANSKI E., NOMEIR A., LIM in humans, 504P which is associated with the poor J., LIN C., GUILLAUME M. & SCHEITHAUER W. see MADER R.M. metabolizer phenotype, 361 AFFRIME M.B. Pharmacokinetic SCHMITT M. see DINGEMANSE J. PARK B.K. see GILL HJ. interaction studies between felbamate SCHOEMAKER R.C. see VAN DEN PARK B.K. see HALLIDAY R.C. and vigabatrin, 157 ANKER JN. PARK B.K. see HOWARD N.J. REISS T. see SCHOORS DF. SCHOORS D.F. see DE SMET M. PARK B.K. see KITTERINGHAM N.R. RENWICK A.G. see RASHID T.J. SCHOORS D.F., DE SMET M., REISS PARK B.K. see MAHMUD R. RENWICK A.G. see ROBERTS J. T., MARGOLSKEE D., CHENG H., PARK B.K. see NAISBITT D.J. RENWICK A.G. see SOWUNMI A. LARSON P., AMIN R. & SOMERS PARK B.K. see TOMLINSON ES. REVELEY M.A. see BURKE J.G. G. Single dose pharmacokinetics, PARK B.K. see WILLIAMS D. REY E. see REIDENBERG P. safety and tolerability of MK-0476, a PARKER D. see MILLER R:S. RICHTER K. see BERNDT A. new leukotriene D4-receptor PATAT A. see FAIRWEATHER D.B. RIDDELL J.G. see SILKE B. antagonist, in healthy volunteers, 277 PATTERSON A. see BARHAM H.M. RIDDELL J.G. see THAM T.C.K. SCHROETER V. see DE MEY C. PEDRAZZOLI Jr J. see MUSCARA RITCHIE R.H. see ZHANG Y. SCHWEER H. see CAWELLO W. M.N. RITTER J.M. see COCKCROFT J.R. SEABER E. see LIPTROT J. PEHOURCQ F. see BANNWARTH B. RIZOVSKI B. see MADER R.M. SEDEK G. see DINGEMANSE J. PEREZ A. see GRANDE L. ROASALKI S.B. see FRASER A.G. SEPPALA T. see VANAKOSKI J. PETERSON D. see PURKISS A.G. ROBERTS D. see DOCKENS R.C. SEYBERTH H.W. see CAWELLO W. PETERSON G.M. see MILLER RS. ROBERTS J., WALLER D.G., O'SHEA SEYMOUR R.A. see MOORE U.J. PEYRIERE H. see HILLAIRE-BUYS N., MACKLIN B.S. & RENWICK SHAFER S.L. see BILLARD V. D. AG. The effect of selegiline on the SHANKS R.G. see THAM T.C.K. PHILIPP TH. see SCHAFERS RF. peripheral pharmacokinetics of SHARAHA A.M., HIGHAM M.A., PHILLIPS G.J. see DAVIES J.G. levodopa in young volunteers, 404 SPANEVELLO A. & IND P.W. PINO R. & LYLES G.A. Toxicity of RODGERS E.H. see WILSON Y. Effects of intradermal injections of allylamine and acrolein towards ROLL S. see DE MEY C. atrial natriuretic peptide, 283 human cultured endothelial cells: ROOTSLANE L. see KIIVET R.A. SHARARA A.M. see HIGHAM M.A. involvement of semicarbazide- ROSENZWEIG P., CAPLAIN H., SHARARA A.M., HIGHAM M.A., sensitive amine oxidase, 187P CHAUFOUR S., ULLIAC N., IREDALE M.J. & IND P.W. PIRMOHAMED M. see HOWARD CABANIS M.J. & THEBAULT Intradermal actions of hypertonic N.J. J.J. Comparative wheal and flare saline involve neural and vascular PIRMOHAMED M. see NAISBITT study of mizolastine terfenadine, mechanisms, 98 DJ. cetirizine, loratadine and placebo in SHENFIELD G.M., STRINGER RSS. & PIRMOHAMED M. see WILLIAMS D healthy volunteers, 459 ATKIN P.A. Can we improve POLLER U. see SCHAFERS RF. ROSENZWEIG P. see prescribers’ knowledge of their elderly POSNER J. see LIPTROT J. FAIRWEATHER D.B. patients’ medications? 512P POUNDER RE. see FRASER A.G. ROSTAMI-HODJEGAN A., SHUKLA U.A. see BARBHATYA R.H. PRINCE L.R. see WIEBKIN P.F. LENNARD L. & LILLEYMAN JS. SIEGMUND W. see BERNDT A. PURKISS A.G., CHARLETT A., The accumulation of mercaptopurine SILKE B., THOMPSON A., LEITCH WRIGHT D.J., CHING D., metabolites in age fractionated red A. & RIDDELL J.G. A placebo PETERSON D., O’NEILL C.J.A., blood cells, 217 controlled comparison of the effects of DOBBS S.M. & DOBBS ROSTAMI-HODJEGAN A., metoprolol and celiprolol on echo- R.J. Immunological status, with NURMINEN S., JACKSON P.R. & Doppler measurements of respect to IgG, IgA and IgM, in TUCKER G.T. Caffeine urinary cardiovascular function in normal sufferers from idiopathic metabolite ratios as markers of volunteers, 37 parkinsonism, their spouses and CYP1A2 activity: specificity and SIM E. see MATAS N. siblings, 513P sensitivity, 508P SIMMS J.P. see FEHER M.D. PUSSARD E. see DURANTEAU J. ROSTAMI-HODJEGAN A., SIMON G. see GARCIA-RODRIGUEZ NURMINEN S., JACKSON P.R. & L.A. RADOMSKI M. see RAMSAY B. TUCKER G.T. Caffeine urinary SIMONS M. see BLAUW G.J. RADWANSKIE. see REIDENBERG P. metabolite ratios as markers of SIMULA A_P. see ELLIS S.W. RAINER H. see MADER R.M. CYP1A2 activity: simulation of SJOQVIST F. see KITVET R.A. RAJAONARISON J.F. see SAMPOL E. population distributions, 509P SKETT P. see AL-SHIBANI N. RAMSAY B., RADOMSKI M., de RUBIN P.C. see COOPER J.A. SKETT P. see KHAN S. BELDER A., MARTIN JF. & SKWARSKI K. see WEBB D.J. LOPEZ-JARAMILLO P. Systemic SAMPOL E., LACARELLE B., SLEVIN MLL. see THOMPSON PI. effects of S-nitroso-glutathione in the RAJAONARISON J.F., CATALIN SMITH D. see HYLAND R. human following intravenous J. & DURAND A. Comparative SMITH D.A see WALKER D.K. infusion, 101 effects of antifungal agents on SMITH D.A. see HALLIDAY R.C. RAMSAY L.E. see YEO W.W. zidovudine glucuronidation by SMITH G. see ELLIS S.W. RAPOPORT D. see DOCKENS R.C. human liver microsomes, 83 SNOECK E. see KAMALI F. RASHID T.J. see SOWUNMI A. SCEMAMA M. see PANFILOV V. SOMERS G. see SCHOORS D.F. RASHID T.J., MARTIN U., CLARKE SCHAEVERBEKE T. see SOMERVILLE D.T. see STRACHAN H., WALLER D.G., RENWICK A.G. BANNWARTH B. FE. & GEORGE C.F. Factors affecting SCHAFERS R.F., POLLER U., DAUL SOWUNMIA., RASHID T.J., © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 609 AKINYINKA 0.0. & RENWICK BACK D.J. & PARK B.K. WALLEY T. & DAVEY P. Meeting A.G. Ethnic differences in nifedipine Dexamethasone metabolism by Report: Pharmacoeconomics: a kinetics: comparisons between human liver in vitro: metabolite challenge for clinical pharmacologists, Nigerians, Caucasians and South identification, 191P 199 Asians, 489 TONKIN A.L. see KNIGHTS K.M. WANWIMOLRUK S., KANG W., SPANEVELLO A. see SHARAHA A.M. TORRENT J. see AZCONA O. COVILLE P-F., SPENCE J.D. see BAILEY D.G. TRAN L.T. see BAILEY D.G. VIRIYAYUDHAKORN S. & STARMER G.A., GIBSON J. & TU T. see GUPTA S.K. THITIARCHAKUL S. Marked MASCORD D.J. Caffeine and the TUCKER G.T. see COLEMAN T. enhancement by rifampicin and lack development of fatigue in a prolonged TUCKER G.T. see ELLIS S.W. of effect of isoniazid on the driving related task, 516P TUCKER GT. see ROSTAMI- elimination of quinine in man, 87 STEGER G.G. see MADER R.M. HODJEGAN A. WANWIMOLRUK S., THOU MLR. & STENING P. see GARDNER LB. TUERSLEY M.D. see DONAVAN WOODS D.J. Evidence for the STEVENSON P. see COCKCROFT AJ.G. polymorphic oxidation of J.R. TURCK D. see DEGNER F.L. debrisoquine in a Khmer STICKNEY J.L. see BILLARD V. TURNER J. see MINTON N.A. (Cambodian) population, 166 STRACHAN F.E., HAYNES W.G., WEBB D.J. see HAYNER W.G. HUTCHEON L.G., LOMAX C.C., UCHIYAMA N. see UEMATSU T. WEBB D.J. see STRACHAN F.E. O’KANE K.P.J., SOMERVILLE UEMATSU T., KANAMARU M., WEBB D.J., FERRO C.J., HAYNES D.T. & WEBB D.J. An investigation KOSUGE K., HARA K., W.G., SKWARSKI K. & WYLD P. into the development of nitrate UCHIYAMA N., TAKENAGA N., Vasodilator effects of the ETA/B tolerance in human forearm resistance TANAKA W., FRIEDMAN BSS. & receptor antagonist, TAK -044, in and capacitance vessels, 504P NAKASHIMA M. Pharmacokinetic humans, 503P STRATFORD LJ. see BARHAM H.M. and pharmacodynamic analysis of a WEDZICHA J.A. see THOMPSON P.I. STREET M. see DAVIES J.G. novel leukotriene biosynthesis WESTENDORP R.G.J. see BLAUW STRINGER R:S. see SHENFIELD inhibitor, MK-0591 in healthy GJ. G.M. volunteers, 59 WHELPTON R. see MICHAEL-TITUS SUKONTASON K. see AUPRAYOON ULLIAC N. see ROSENZWEIG P. AT. P. UPWARD J. see COMPTON C. WHITTINGHAM T. see WYNNE H. SZABADI E. see ABDELMAWLA A.H. WIEBKIN P-.F., PAGE K.M., PRINCE SZAWLOSKI P. see CRAWFORD D. VALLANCE P. see BHAGAT K. L.R., GUNRAJ P.E. & MALLETT VALLANCE P. see DAVIES G. C.D. A high-sensitivity assay for the TAKENAGA N. see UEMATSU T. VAN BRUMMELEN P. see determination of RP 73401 in human TAN K.S., GROVE A., CARGILL R.L, DINGEMANSE J. plasma using h.p.l.c with on-line McFARLANE L.C. & LIPWORTH VAN DEN ANKER J.N., HOP W.C.J., fluorescence detection, 197P B.J. Effects of inhaled fluticasone SCHOEMAKER R.C. & VAN DER WILLIAMS A.J. see DONAVAN A.J.G. HEIJDEN B.J. Ceftazidime WILLIAMS D, MAGGS J.L., propionate and oral prednisolone on pharmacokinetics in preterm infants: PIRMOHAMED M. & PARK B.K. lymphocyte B2-adrenoceptor function effect of postnatal age and postnatal Bioactivation of clozapine in vitro and in asthmatic patients, 506P TANAKA W. see UEMATSU T. exposure to indomethacin, 439 in vivo: implications for drug-induced VAN DER HEIJDEN B.J. see VAN agranulocytosis, 182P TANG B. see NOORMOHAMED F.H. DEN ANKER J.LN. WILLIAMS D.P. see NAISBITT D.J. TANI M. see KOBAYASHI K. VAN DER HEIJDEN B.J. see WALKER WILSON Y, RODGERS E.H. & TATEISHI T., GRAHAM S.G., D.K. GRANT M.H. Ethacrynic acid KRIVORUK Y. & WOOD VAN DER WAL G. see LIJESEN G.K.S modulates the in vitro cytotoxicity of A.J.J. Letter to the Editor: VANAKOSKI J., MATTILA M.J. & mitoxantrone in MCF 7 human Omeprazole does not affect measured SEPPALA T. Grapefruit juice does breast cancer cells, 190P CYP3A4 activity using the not interact with midazolam in man, WISSEL K. see GEISSLINGER G. erythromycin breath test, 411 520P WITHEROW L.E., GIFFORD L.A. & TESSMAN J.W. see BILLARD V. VEAL G.J. see HOGGARD P.G. HOUSTON J.B. Metabolism and THAM T.C.K., GUY S., McCDERMOTT VEGA JS. see KIIVET R.A. covalent binding of furazolidone in B.J., SHANKS R.G. & RIDDELL VENTRESCA G.P. see MACKIE A.E. vitro in pig liver and muscle fractions, J.G. The dose dependency of the « VERBESSELT R. see DE SMET M. 187P and B-adrenoceptor antagonist VERE D.W. Actions of terfenadine and WOLF C.R. see ELLIS S.W. activity of carvedilol in man, 19 cimetidine on histamine wheal WOO KS. & NICHOLLS M.G. High THEBAULT J.J. see ROSENZWEIG P. formation, 557 prevalence of persistent cough with THEEUWEN |. see LIJESEN G.K.S VEYSSIER-BELOT C. see AZIZI M. angiotensin converting enzyme THITIARCHAKUL S. see VIERKANT A. see BERNDT A. inhibitors in Chinese, 141 WANWIMOLRUK S. VINCENT-VIRY M. see PANSERAT S. WOOD A.J.J. see TATEISHI T. THOMAS S.H.L. see KAMALI F. VIRIYAYUDHAKORN S. see WOODS D.J. see WANWIMOLRUK S. THOMPSON A. see SILKE B. WANWIMOLRUK S. WORBOYS P.D., BRADBURY A. & THOMPSON P.L., JOEL S.P., JOHN L., HOUSTON J.B. A comparison of the WEDZICHA J.A., MACLEAN M. & WAINER I.W. see DUCHARME J. kinetics of caffeine and phenytoin SLEVIN MLL. Respiratory depression WALKER D.K., VAN DER HEIJDEN metabolism in precision cut liver following morphine and morphine-6- B.J., SMITH D.A, NEIJENS H.J. & slices and freshly isolated hepatocytes, glucuronide in normal subjects, 145 DE GROOT R. Differentiation of 188P THOU MLR. see WANWIMOLRUK S. compounds which bind to P450 WRIGHT CLE. see OO C.Y. THYGESEN P. see MATAS N. isozymers CYP2C9 and CYP3A4 by WRIGHT D.J. see PURKISS A.G. TINGLE M_D. see GILL HJ. physicochemical properties, 178 P WRITER D.J. see BULLIMAN S. TINGLE M.D. see MAHMUD R. WALLER DG. see RASHID T.J. WYLD P. see WEBB D.J. TOMLINSON E.S., MAGGS J.L., WALLER D.G. see ROBERTS J. WYNNE H., COPE L., KELLY P., © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 610 Index WHITTINGHAM T., EDWARDS C. YEO W.W., CHADWICK I.G., ZARIFFA N. see BULLIMAN S. & KAMALIF. The influence of age, KRASKIEWICZ M., JACKSON ZAYAS J.M. see GRANDE L. liver size and enantiomer P.R. & RAMSAY L.E. Resolution of ZHANG Y., RITCHIE R.H. & concentrations on warfarin ACE inhibitor cough: changes in HOROWITZ J.D. Postextrasystolic requirements, 203 subjective cough and responses to potentiation in patients with inhaled capsaicin, intradermal ischaemic heart disease: influence of bradykinin and substance-P, 423 inotropic agents, 25 YAMAMOTO T. see KOBAYASHI K. YOULE MSS. see NOORMOHAMED ZOMORODI K. see CARLILE D.J. YAQUB Z. see MICHAEL-TITUS A.T. F.H. ZURCHER G. see DINGEMANSE J. © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Br J Clin Pharmacol 1995; 40: 611-613 SUBJECT INDEX This index is compiled from the keywords (P = Proceedings) Absorption, 387 Caffeine, 188P, 393, SO8P, SO9P, 516P Debrisoquine, 166 ACE inhibitor, 423 Calcium, 502P Desipramine, 263, 445 Acetyltransferase, 193P Cancer, 553 Dexamethasone, 181P, 192P Acrolein, 187P Capsaicin, 423 Dexamethasone metabolism, 191P Adrenal medulla, 263 Captopril, 31, 141 Diadenosine phosphates, 170 Adrenaline, 263, 453 Cardiovascular reflexes, 431 Diastole, 299 Adrenergic receptor blockade, 504P Carvedilol, 19 Diazepam, 181P Adverse drug reactions, 173 Cat, 183P Diet, 237 Age, 203 Caucasians, 489 Digoxin, 571 Agranulocytosis, 182P Cefpirome, 521P Dimethylnitrosamine, 193P Agreement, 291 Ceftazidime, 439 Dinamap, 291 Airway resistance, 539 Celiprolol, 37 Diol formation, 180P Alcohol, 393 Central nervous system, 266, 393 Dorsal hand vein, 443 Allylamine, 187P Cephalosporin, 521P Dose dependency, 19 Alpha-adrenoceptor antagonism, 19 Cerebral ischaemia, 507P Dose proportional pharmacokinetics, 273 Alpha,-adrenoceptors, 443 CGS 21680, 43 Driving-related task, 516P Alprazolam, 231 Chemiluminescence, 31 Drug administration-inhalation, 76 Analgesics, 111, 339, 545 Chemo-somatosensory, 339 Drug delivery devices, 76 Angiotensin II, 591 Chemo-somatosensory event-related Drug interaction, 87, 161, 598 Angiotensin II blockade, 505P potentials, 545 Drug subsidy, 407 Angiotensin converting enzyme Chicken pox, 513P Drug therapy, 199 inhibitors, 141, 415 Childhood leukaemia, 217 Drug use, 79, 407, 467 Angiotensin receptors, 591 Children, 79 DuP, 753, 571 Anticancer agents, 523 Chinese, 141 Dynamic exercise, 563 Antidepressants, 119 Chiral inversion, 153 Antifungal agents, 83 Cholestyramine, 92 Echo-Doppler, 37 Antimalarial drugs, 511P Chronic liver disease, 494 Economics, 199 Antimycotics, 270 Cimetidine, 161, 519P, 557 (E)-5-(2-bromoviny] )uracil, 189P Appetite, 237 Circulation, 415 Elderly, 325, 512P Asians, 166 Cirrhosis, 477 Electrostatic charge, 76 Aspartic acid, 178P Citalopram, 481 Enalapril, 141 Aspirin, 111 Clozapine, 182 P Enalaprilat, 415 Asthma, 76, 539, 506P, 518P Codeine, 111 Enantiomers, 127, 339 Atenolol, 563 Cognitive function, 119 Enantioselective pharmacokinetics, 67 AT, angiotensin II receptors, 571 Cohort study, 79 Endothelium, 307 Atrial natriuretic peptide, 283 Colestipol, 92 Endotoxin, 502P A>, adenosine receptor, 43 Colorectal cancer, 209 Enzyme induction, 87 Autoantibodies, 379 Comet assay, 193P Epoxide hydrolase, 180P Autonomic function, 563 COMT inhibition, 253 Epoxide hydrolase, 509P Concentration-effect relationship, 253 Erythrocytes, 253 B-acetyl-digoxin, 486 Continuous arterio-venous Erythromycin breath test, 411 B-adrenoceptor antagonist, 19, 25, 313, haemofiltration, 95 ET,, g receptor antagonist, 503P 453, 519P Coronary vasoconstriction, 245 Ethacrynic acid, 190P B-adrenoceptor blockade, 37 Corticosteroids, 76 Ethanol, 387 B-adrenergic receptors, 453 Cough, 141 Ethnic differences, 51, 498 BRL 49653C, 517P Coumarin, 196P Evaluation, 199 BRL 55834, 518P Critically ill, 415 Event-related potentials, 339 B,-adrenoceptor, 506P CYP1A2, 193, 508P, SO9P Exercise, 37, 514P, 521P Bias, 291 CYP3A, 51, 179P, 195P Bioavailability, 51 CYP3A enzymes, 489 Fat distribution, 237 Bioflavonoids, 51 CYP3A4, 369, 135, 178P Fatigue, 516P Bisphosphonates, 183P CYP3A4 activity, 411 Felbamate, 157 Bladder carcinogens, 521P CYP2C9, 178P Felodipine, 135 Blood pressure, 223, 291, 307, 307, 391 CYP2D, 189P Fentanyl, 553 Blood pressure monitoring, 223 CYP2D allele, 361 Finapres, 291 Blood-milk, 231 CYP2D6, 369, 178P, 194P Finger pulse, 291 Bradykinin, 423 Cystic fibrosis, 319 5-fluorouracil, 189P Breast cancer, 194 Cytochrome P-450, 135, 509P, 510P, 523, 5-hydroxytryptamine, 245 Breast cancer cells, 190P 531 5-lipoxygenase inhibitor, 59 Breast feeding, 231 Cytochrome P450-debrisoquine, 5-methyltetrahydrofolic acid, 209 Breast milk, 333 4-hydroxylase, 361 Flare, 98, 283, 459 Bronchodilator, 539 Fluoxetine paroxetine, 481 Budesonide, 76 DMSO, 186P Flurbiprofen, 339 Bufuralol, 189P Dapsone, 510P, 511P, 531 Fluticasone propionate, 198P, 506 © 1995 Blackwell Science Ltd 611 612 Index Food, 387, 517P Leukotriene B4, 59 Parkinson’s disease, 253 Food-drug interaction, 135 Levodopa, 253, 401, 404 P450 isoenzymes, 178P Forearm blood flow, 591 Lignocaine, 98 P4502E1, 193P Foscarnet, 502P Litoxetine, 119 P-Glycoprotein, 523 Furazolidine, 187P Liver microsomes, 83 Pharmaco-epidemiology, 79 Liver size, 203 Pharmacodynamics, 37, 145, 253, 325, Gastrointestinal sphincter, 401 Losartan, 431, 571 519P, 521P Gastro-oesophageal sphincter, 401 Low molecular weight heparins, 577 Pharmacoepidemiology, 407 Gender, 153, 325 Lower body negative pressure, 431 Pharmacogenetics, 166 Genetic polymorphism, 361 Lung cancer, 194P Pharmacokinetic interaction, 486, 521P Glucuronidation, 83 Pharmacokinetics, 59, 87, 95, 119, 127, Glutathione, 180, 511P Magnesium, 502P, 539 153, 209, 231, 253, 277, 319, 325, 347, Glycogen phosphorylase, 185P Manometry, 401 404, 439, 477, 494, 507P, 517P, 518P, Grapefruit, 135 Market uptake, 407 553, 577 Grapefruit juice, 51, 520P Meloxicam, 486 Pharmacological effects, 319 Guanamines, 185 P Mental stress, 563 Phenytoin, 183P Mercaptopurine, 217 Phenytoin metabolism, 188P Haemodialysis, 521P Meta-analysis, 237 Photodynamic therapy, 594 Haemodynamics, 415 Metabolism, 477, 531 Plasma and CSF concentrations, 266 Haemofiltration, 95, 521P Metabolites, 273, 481 Plasma concentrations, 553 Haemotoxicity, 51iP Methyleugenol, 196P Platelet aggregation, 101 Halofantrine, 195P, 369 Metoprolol, 37, 189P PMA, 31 Halothane, 379 Metronidazole, 477 Poor metabolizer, 361 HCG, 237 Microcirculation, 415 Postextrasystolic potentiation, 25 Healthy volunteers, 119, 431, 459, 577 Microsomes, 369 Postnatal age, 439 Heart failure, 141 Midazolam, 270, 520P Potassium channel activator, 518P Hepatitis, 379 Milrinone, 25 PPAR RNAs, 184P Histamine, 557 Mitoxantrone P, 190 Prediction model, 231 H, antihistamine, 459 MK-0476, 277 Prednisolone, 506 HIV infection, 107, 502 MK-0591, 59 Prescribers’ knowledge, 512P Human arylamine N-acetyltransferase, MK-954, 571 Presynaptic sodium channel inhibitors, 522P Modelling, 253 507P Human chorionic gonadotropin, 237 Monoamine transporter, 263 Preterm infants, 439 Human coronary artery, 245 Morphine, 145, 517P Proguanil, 166 Human liver microsomes, 192P Morphine-6-glucuronide, 145 Propranolol, 521P Human platelets, 43 MPG, 31 Prostaglandin E1, 273 Human serum lipo-proteins, 594 MST continus, 517P Protein binding, 594 Human skin, 283, 557 Muscarinic receptor blockade, 504P Protirelin, 223 Hydrocortisone, 186P Psychomotor performance, 119 Hydroxychloroquine, 127 NECA, 43 Psychomotor tests, 563 Hydroxylamine, 531 Natriuretic peptides, 11, 585 Psychophysiological measurements, 393 Hyperlipidaemia, 92 Nebivol, 519P Pulmonary circulation, 11, 313, 585 Hypertension, 141, 563 Nebuliser, 313 Pulmonary vasoconstriction, 505P Hypertonic saline, 98 Nefazodone, 161, 598 Hypoxaemia, 11, 313, S06P, 585 Nephrotoxicity, 67 Quinine, 87 Hypoxia, 453 Neuroleptics, 467 Ranitidene, 519P Neuronal uptake, 263 Ibuprofen, 67, 266 RB90740, 181P Nifedipine, 51, 489 Idiopathic parkinsonism, 513P Red cell metabolism, 217 Nigerians, 489 Imipramine, 194P 9-methoxypsoralen, 347 Regional blood flows, 431 Immunological status, 513P Renal haemodynamics, 67 Nitrate tolerance, 504P Immunosuppressants, 507P Nitric oxide, 101, 299 Renin-angiotensin system, 11 In vitro metabolism, 369 Respiratory depression, 145 Non-prescription drugs, 79 In vitro technique, 333 Non-steroidal anti-inflammatory drugs, Retinoid-induced bone resorption P, 183 In-patients, 467 266 (R)-ibuprofen, 153 Indomethacin, 439 Rifampicin, 87 Noradrenaline, 263, 453, 504P Infusion, 273 Right ventricular function, 415 Noradrenaline methoxamine, 443 Inhalation, 281 Rilmenidine, 563 Inhibition, 531 RP, 73401, 197 Insulin, 186P Obesity, 237 Interaction, 270, 393 Oesophagus, 401 Salbutamol, 319, 506P Omeprazole, 411 Intravenous, 347 Saralasin, 505P Isoniazid, 87 Oral contraceptive steroids, 153 Schistosomiasis, 477 Isoprenaline, 291 Oramorph SR, 517P Schizophrenia, 467, 515P Organ perfusion, 415 Selegiline, 401, 404 Khmers, 166 Oscillometry, 291 Semicarbazide-senstive amine oxidase, Korotkoff sounds, 291 Oxidation polymorphism, 166 187P Oxygen uptake, 31 Setraline, 481 LTD4-receptor antagonist, 277 Simeons, 237 Lactose, 281 Pancopride, 401 Sino atrial node modulator P, 514 Left ventricle, 299 Paracetamol, 79, 111 Slow-release formulation, 135 © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 611-613

ebook img

British Journal of Clinical Pharmacology 1995: Vol 40 Index PDF

11 Pages·1995·3.8 MB·English
by  
#periodicals #sim_microfilm #pub_british-journal-of-clinical-pharmacology
Save to my drive
Quick download
Download
Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.

Preview British Journal of Clinical Pharmacology 1995: Vol 40 Index

Br J Clin Pharmacol 1995; 40: 603-610 AUTHOR INDEX (P = Proceedings) ABBOTT F. see MILLER RS. BACK D.J. see BARRY M.G. absorption of [14]C -coumarin in ABDELMAWLA A.H., LANGLEY BACK D.J. see GENTILE D.M. human skin, 196P R.W., SZABADI E. & BRADSHAW BACK D.J. see HOGGARD P.G. BEEDHAM C. see OLDFIELD S. C.M. Comparison of the effects of BACK D.J. see TOMLINSON ES. BELK D. see NOTARIANNI L.J. desipramine on noradrenaline-and BAILEY D.G., ARNOLD J.M.O., BELL D.R & JONES P.S Hepatic methoxamine-evoked BEND J.R., TRAN L.T. & SPENCE expression of mouse PPAR RNAs P, venoconstriction in man, 443 J.D. Grapefruit juice-felodipine 184 ABDULLAH I. see CLAPPERTON M. interaction: reproducibility and BELZ GG. see DE MEY C. AFFRIME M.B. see REIDENBERG P. characterization with the extended BEND J.R. see BAILEY D.G. AGOSTINIS L. see GARCIA- release drug formulation, 135 BENNETT P.N. see NOTARIANNI L.J. RODRIGUEZ L.A. BAILEY J.E. see COUPLAND N.J. BERDEAUxX A. see DURANTEAU J. AHONEN J., OLKKOLA K.T. & BALL D.E. & KAMALI F. Phenytoin BERGIN P. see GARDNER LB. NEUVONEN P.J. Effect of metabolism to 5 (4-hydroxy-phenyl)- BERNDT A., HOFFMAN C., itraconazole and terbinafine on the 5-phenylhydantoin in the cat is not RICHTER K., OERTEL R., pharmacokinetics and inhibited by sulphaphenazole, 183P VIERKANT A. & SIEGMUND W. pharmacodynamics of midazolam in BANFIELD C. see REIDENBERG P. Letter to the Editor: Tiracizine healthy volunteers, 270 BANMAIRUROI V. see disposition in healthy volunteers with AIACH M. see AZIZI M. AUPRAYOON P. reference to the debrisoquine AIRD S.A. see NOTARIANNI L.J. BANNWARTH B., LAPICQUE F., oxidation phenotype, 287 AKINYINKA 0.0. see SOWUNMI A. PEHOURCQ F., GILLET P., BESWICK P.H. see CLAPPERTON M. AL-SHIBANI N. & SKETT P. A change SCHAEVERBEKE T., LABORDE BHAGAT K., COLLIER J. & in the effect of guanamines on C., DEHAIS J..GAUCHER A. & VALLANCE P. Endotoxin-induced glycogen phosphorylase a activity in NETTER P. Stereoselective venous hyporesponsiveness in hepatocytes from streptozotocin disposition of ibuprofen enantiomers humans, 502P diabetic rats in different glucose in human cerebrospinal fluid, 266 BILLARD V., GAMBUS P.L., BARR J., concentrations, 185P BARBANOJ M.J. see AZCONA O. MINTO C-F., CORASH L., AL-SHIBANI N. & SKETT P. The effect BARBHATYA R.H. see DOCKENS R.C. TESSMAN J.W., STICKNEY J.L. & of guanamines (cyclised biguanides) BARBHATYA R.H., SHUKLA U.A. & SHAFER S.L. The pharmacokinetics on glycogen phosphorylase a activity GREENE D5. Lack of interaction of 8-methoxypsoralen following i.v. in hepatocytes from normal rats in between nefazodone and administration in humans, 347 different glucose concentrations, 185P cimetidine:steady state BILLAUD-MESGUISH E. see ALEXANDER §S.P.H. see COOPER J.A. pharmacokinetic study in humans, AZIZI M. ALHENC-GELAS M. see AZIZI M. 161 BIRKETT D.J. & McMANUS P. ALTYAR C.A. see DRAKE J. BARCELO S., GESCHER A. & Modelling the market uptake of new ALLEN A. see BULLIMAN S. CHIPMAN J.K. Sulphoraphane drugs following listing for subsidy in ALLOTT R.L. see HOWARD N.J. exhibits cytochrome Australia. A report from the Drug ALSPAC Survey Team see P4502E1-mediated activation of Utilisation Subcommittee of the HAWKINS N. dimethylnitrosamine, 193P Australian Pharmaceutical Benefits AMIN R. see SCHOORS D-F. BARHAM HLM. & STRATFORD Advisory Committee, 407 ANDREWS H.B. see BURKE J.G. IJ. Enzymology of the bioreduction BLAUW G.J.. WESTENDORP R.G,J., ARNOLD J.M.O. see BAILEY D.G. of the pyrazine mono-N-oxide SIMONS M., CHANG P.C., ARTHURS N. see HALL M. RB90740: roles for cytochrome P450 FROLICH M. & MEINDERS A.E. ASHTON C.H. see MOORE UJ. reductase and cytochrome b, release, Beta-adrenergic receptors contribute ASSENDELFT W.J.J. see LIJESEN 181P to hypoxaemia induced G.K.S BARHAM H.M., CHINJE E.C., vasodilatation in man, 453 ATKIN P.A. see SHENFIELD G.M. PATTERSON A. & STRATFORD BOGLE R.G. see DAVIES G. ATKINSON L. see GUPTA S.K. I.J. Toxicity of the bioreductive drug BOLDT J., MATTHIAS M., HEESEN AUPRAYOON P., SUKONTASON K., SR 4233 (tirapazamine) is determined M., HARTER K. & NA-BANGCHANG K., by P450 reductase activity in human HEMPELMANN G. BANMAIRUROI V., MOLUNTO P. breast but not lung cancer lines, 194P Cardiorespiratory effects of & KARBWANG J. Pharmacokinetics BARR J. see BILLARD V. continuous i.v administration of the of quinine in chronic liver disease, 494 BARRY M.G. see HOGGARD P.G. ACE inhibitor enalaprilat in the AZCONA O., BARBANOJ M.J., BARRY M.G., BACK D.J. & critically ill, 415 TORRENT J. & JANE F. Evaluation BRECKENRIDGE A.M. Zidovudine BONN R. see CAWELLO W. of the central effects of alcohol and therapy in HIV infection: which BOON N.A. see NEWBY D.E. caffeine interaction, 393 patients should be treated and when, BRADBURY A. see WORBOYS P.D. AZIZI M., VEYSSIER-BELOT C., 107 BRADSHAW C.M. see ALHENC-GELAS M., BARRY P.W. & O’CALLAGHAN C. ABDELMAWLA A.H. CHATELLIER G., BILLAUD- The effect of delay, multiple BRECKENRIDGE A. The Lilly Lecture, MESGUISH E., FIESSINGER J.N. actuations and spacer static charge on 1994: Science, medicine and clinical & AIACH M. Comparison of the in vitro delivery of budesonide pharmacology, | biological activities of two low from the Nebuhaler, 76 BRECKENRIDGE A.M. see BARRY molecular weight heparins in 10 BECKLEY-KARTEY S.A.J. & MG. healthy volunteers, 577 HOTCHKISS S.A.M. Topical in vitro BRENNAN BS. see CARLILE D.J. © 1995 Blackwell Science Ltd 603 604 Index BRES J. see HILLAIRE-BUYS D. CHINJE E.C. see BARHAM H.M. DALEY-YATES P.T. see McCAPPIN BRETT S.E. see COCKCROFT J.R. CHIPMAN J.K. see BARCELO S. T.R. BRITTON J. see HILL J. CHIPMAN J.K., DAVIES J.E., DASH DARGIE H.J. see CLAPPERTON M. BRODDE O.-E. see SCHAFERS R.F. P. & DOEHMER J. Use of the DASH P. see CHIPMAN J.K. BROWN M.J. see FERRO A. Comet assay to detect activation of, DAUL A.E. see SCHAFERS RF. BRUNE K. see GEISSLINGER G. 2-amino-3methylimidazo (4,5-f) DAVEY P. see WALLEY T. BRUNE K. see LOTSCH J. quinoline (IQ) in V79 cells expressing DAVIDSON C. see IVERSEN S.A. BULLIMAN S., ALLEN A., HARRIS CYP1A2 and acetyltransferase, 193P DAVIDSON D. see IVERSEN S.A. A.M., WRITER D.J., FREED ML, CHOWIENCZYK PJ. see DAVIES C.D. see HOWARD N.J. DICICCO R., ZARIFFA N. & COCKCROFT JR. DAVIES G., MacALLISTER R.J., JORKASKY D.K. The influence of CLAPPERTON M., BESWICK P.H., BOGLE R.G. & VALLANCE P. food on the pharmacokinetics of BRL ABDULLAH L., DARGIE H.J., Effect of diadenosine phosphates on 49653C in healthy male volunteers, FISHER A.C. & McMURRAY human umbilical vessels: novel 517P J. Effect of captopril, enalaprilat and platelet-derived vasoconstrictors, 170 BULLMAN J. see COMPTON C. mercaptopropionyl glycine (MPG) on DAVIES J.E. see CHIPMAN J.K. BURKE J.G., DURSUN S.M., the oxidative activity of human DAVIES J.G., PHILLIPS G.J., OLLIFF REVELEY M.A. & ANDREWS H.B. isolated neutrophils, 31 C.J., STREET M. & KINGSWOOD Effects of sulpiride on voluntary CLARKE H. see RASHID T.J. C. A comparison of cefpirome saccadic eye movements (VSEMs) in CLARKE S.E. see OLDFIELD S. clearance by in vitro models of schizophrenia, 515P CLARKSON P.B.M., LIM P.O. & haemofiltration and haemodialysis, 521 BURKE M_D see EKINS S. MacDONALD T.M. Influence of DE ABAJO F. see MARTIN ARIAS L.H. BUTZER R. see DE MEY C. basal nitric oxide secretion on cardiac de BELDER A. see RAMSAY B. BYE A. see MACKIE AE. function in man, 307 DE GROOT R. see WALKER D.K. COCKCROFT J.R., CHOWIENCZYK DE MEY C., SCHROETER V., CABANIS M.J. see ROSENZWEIG P. P.J., BRETT S.E., MANT T.G.K., BUTZER R., ROLL S. & BELZ G.G. CALDWELL J. see GARDNER LB. DURNIN C., LYNN F., Method specificity of non-invasive CAPLAIN H. see ROSENZWEIG P. STEVENSON P. & RITTER J.M. blood pressure measurement: CARGILL R.I. & LIPWORTH The effect of HN-65021 on responses oscillometry and finger pulse pressure B.J. Acute effects of ANP and BNP to angiotensin II in human forearm vs acoustic methods, 291 on hypoxic pulmonary vasculature, 591 DE MEYER G. see DE SMET M. vasoconstriction in humans, 585 COLEMAN T., LENNARD MSS. & DE NUCCI G. see MUSCARA M.N. CARGILL R.I. & LIPWORTH B.J. The TUCKER G.T. Metabolism of the DE SMET M. see SCHOORS D-F. role of the renin-angiotensin and CYP2D substrates metoprolol and DE SMET M., SCHOORS D.F., DE natriuretic peptide systems in the bufuralol by rat brain and liver MEYER G., VERBESSELT R., pulmonary vasculature, 11 microsomes, 189P GOLDBERG M.R. & CARGILL R.I. see KIELY D.G. COLLIER J. see BHAGAT K. FITZPATRICK V. Effect of multiple CARGILL R.I. see TAN K:S. COLUCCI R. see REIDENBERG P. doses of losartan on the CARLILE D.J.. BRENNAN B5., COMPTON C., BULLMAN J., DOYLE pharmacokinetics of single doses of ZOMORODI K. & HOUSTON J.B. E., DURIE S., GEORGIOU P., digoxin in healthy volunteers, 571 Induction of diazepam clearance in HIGGINS R., UPWARD J. & KAYE DEARDEN J.C. see MAHMUD R. vitro in rat by dexamethasone: C. The pharmacokinetics of oral BRL DEGNER F.L., HEINZEL G., NARJES quantitative predictions from 55834 in healthy male subjects, 518 P H. & TURCK D. The effect of microsomal and hepatocyte studies, COOPER J.A., HILL S.J, meloxicam on the pharmacokinetics 18iP ALEXANDER §.P.H., RUBIN P.C. of beta-acetyl-digoxin, 486 CARROLL K. see DONAVAN A.J.G. & HORN E.H. Adenosine receptor- DEHAIS J. see BANNWARTH B. CARVAJAL A. see MARTIN ARIAS induced cyclic AMP generation and DEMNATI R., MICHOUD M.C., L.H. inhibition of 5-hydroxytryptamine JEANNERET-GROSJEAN A. & CATALIN J. see SAMPOL E. release in human platelets, 43 DU SOUICH P. Plasma CATTARUZZI C. see GARCIA- COPE L. see WYNNE H. concentrations and effects of RODRIGUEZ L.A. CORASH L. see BILLARD V. salbutamol administered orally to CAWELLO W., LEONHARDT A., COUPLAND N.J., BAILEY J.E., GLUE patients with cystic fibrosis, 319 SCHWEER H., SEYBERTH H.W., P. & NUTT D.J. The cardiovascular DESAI N. see OO CY. BONN R. & LOMELI A.L. Dose and subjective effects of thyrotropin DESPAUX E. see HILLAIRE-BUYS D. proportional pharmacokinetics of releasing hormone (TRH) and a DICICCO R. see BULLIMAN S. alprostadil (prostaglandin E1) in stable analogue, dimethyl proline- DINGEMANSE J., JORG K., healthy volunteers following TRH, in healthy volunteers, 223 ZURCHER G., SCHMITT M., intravenous infusion, 273 COVILLE P-F. see SEDEK G., DA PRADA M. & VAN CHADWICK LG. see YEO W.W. WANWIMOLRUK S. BRUMMELEN P. Pharmacokinetic- CHANG P.C. see BLAUW G.J. CRAWFORD D., MADDOCKS J.L., pharmacodynamic interaction CHARLETT A. see PURKISS A.G. JONES D. & SZAWLOSKI P. between the COMT inhibitor CHATELLIER G. see AZIZI M. Rational design of tolcapone and single-dose levodopa, CHAUFOUR S. see ROSENZWEIG P. immunosupressants: thioethers- 253 CHEN C.-S. see CHEN C.-Y. azothioprine analogues without bone DJAVANMARD M.P. see MADER CHEN C.-Y. & CHEN C--S. marrow toxicity, 507P R.M. Stereoselective disposition of CRAWFORD FE. see DRAKE J. DOBBS R.J. see PURKISS A.G. ibuprofen in patients with CRONIN M.T.D. see MAHMUD R. DOBBS S.M. see PURKISS A.G. compromised renal haemodynamics, CURSON V.H. see FAIRWEATHER DOCKENS R.C., RAPOPORT D., 67 D.B. ROBERTS D., GREENE D.D. & CHENG H. see SCHOORS D.F. BARBHATYA R.H. Lack of an effect CHIBA K. see KOBAYASHI K. DA PRADA M. see DINGEMANSE J. of nefazodone on the CHING D. see PURKISS A.G. DAHL M. see KIIVET R.A. pharmacokinetics and © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 605 pharmacodynamics of theophylline DUNMORE C., DUBRUC C. & GIFFORD L.A. see WITHEROW L.E. during concurrent administration in HINDMARCH I. The psychomotor GILL H.J., TINGLE M.D. & PARK patients with chronic obstructive and cognitive effects of litoxetine in B.K. Metabolism of dapsone by pulmonary diseases, 598 young and middle aged volunteers, multiple isoforms of human DOEHMER J. see CHIPMAN J.K. 119 cytochrome P450, 510P DONAVAN A.J.G., WILLIAMS A.J., FEELY J. see HALL M. GILL H.J., TINGLE M.D. & PARK K. CARROLL K. & TUERSLEY M.D. FEHER M.D., SIMMS J.P. & LANT N-Hydroxylation of dapsone by Specificity of heart rate reduction by A.F. Steroid cards, chicken pox and multiple enzymes of cytochrome ZD7288, a sino atrial node doctor/patient communication, 513P P450: implications for inhibition of modulator, as assessed by FERRAZ J.G. see MUSCARA MLN. haemotoxicity, 531 transthoracic electrical bioimpedance FERRO A., LONGMORE J., HILL GILLET P. see BANNWARTH B. (TEB) during exercise in healthy R.G. & BROWN M.J. A comparison GIUDICELLI J. see DURANTEAU J. males, 514P of the contractile effects of 5-hydroxy- GLUE P. see COUPLAND N.J. DONNELLY R. see PANFILOV V. tryptamine, sumitriptan and MK-462 GLUE P. see REIDENBERG P. DOYLE E. see COMPTON C. on human coronary artery in vitro, GOLDBERG M.R. see DE SMET M. DRAKE J., ALITYAR C.A., 245 GOLDING J. see HAWKINS N. KIRK PATRICK C.T., CRAWFORD FERRO CJ. see WEBB D.J. GOLDSTEIN DSS. see EISENHOFER F.E., GIBSON P. & HORTH C.E. FIEGER H. see DUCHARME J. G. Effects of food on the FIESSINGER J.N. see AZIZI M. GORCHEIN A. Letter to the Editor: pharmacokinetics of two controlled FISHER A.C. see CLAPPERTON M. Treatment of Parkinson’s disease in a release oral morphine formulations, FITZPATRICK V. see DE SMET M. patient with acute intermittent oramorph SR and MST continus, FLORIN S. see LOTSCH J. porphyria, 105 517P FRASER A.G., ROASALKI S.B., GRAHAM S.G. see TATEISHI T. DU SOUICH P. see DEMNATI R. GAMBLE G.D. & POUNDER RE. GRANDE L., LACIMA G., PEREZ A. DUBRUC C. see FAIRWEATHER D.B. Inter-individual and intra-individual & ZAYAS J.M. Lack of effect ofa DUCHARME J., FIEGER H., variability of ethanol concentration- 5-HT3 antagonist, pancopride, on DUCHARME M.P., KHALIL time profiles: comparison of ethanol lower oesophageal sphincter pressure S.K.W. & WAINER LW. ingestion before or after an evening in volunteers, 401 Enantioselective disposition of meal, 387 GRANT M.H. see WILSON Y hydroxychloroquine after a single oral FREED M.I. see BULLIMAN S. GRAY A.J. see NEWBY D.E. dose of the racemate to healthy FRIBERG P. see EISENHOFER G. GRAZIA TRONCON M. see GARCIA- volunteers, 127 FRIEDMAN BSS. see UEMATSU T. RODRIGUEZ L.A. DUCHARME M.P. see DUCHARME J. FROLICH M. see BLAUW G.J. GREENE D.D. see DOCKENS R.C. DUNMORE C. see FAIRWEATHER GREENE DS. see BARBHATYA R.H. D.B. GALTEAU M.M. see PANSERAT S. GROVE A. see TAN K:.S. DURAND A. see SAMPOL E. GAMBLE G_D. see FRASER A.G. GUILLAUME M. see REIDENBERG DURANTEAU J., PUSSARD E., GAMBUS P.L. see BILLARD V. Pp. BERDEAUX A. & GIUDICELLI GARCIA-RODRIGUEZ L.A., GUNRAJ P.E. see WIEBKIN P-F. J. Effects of the angiotensin type 1 CATTARUZZI C., GRAZIA GUPTA S.K., ATKINSON L., TU T. & receptor antagonist, losartan, on TRONCON M., AGOSTINIS L. & LONGSTRETH J.A. Age and gender systemic and regional vascular SIMON G. Letter to the Editor: related changes in stereoselective responses to lower body negative Acute liver injury and droxicam use in pharmacokinetics and pressure in healthy volunteers, 431 DURIE S. see COMPTON C. the region of Friuli-Venezia Giulia, pharmacodynamics of verapamil and 104 norverapamil, 325 DURNIN C. see COCKCROFT JR. DURSUN S.M. see BURKE J.G. GARDNER LB., BERGIN P., GUY S. see THAM T.C.K. STENING P., KENNA J.G. & EDWARDS C. see WYNNE H. CALDWELL J. Immunochemical HALL M., McCORMAC P., ARTHURS EICHELBAUM M. see KIVISTO K.T. detection of covalently modified N. & FEELY J. The spontaneous EISENHOFER G., FRIBERG P., hepatic proteins produced following reporting of adverse drug reactions by GOLDSTEIN DS. & ESLER M. administration of methyleugenol to nurses, 173 Differential actions of desipramine on rats, 196P HALLIDAY R.C., JONES B.C., SMITH sympathoadrenal release of GAUCHER A. see BANNWARTH B. D.A. & PARK B.K. Halofantrine is a noradrenaline and adrenaline, 263 GAZZARD B.G. see substitute of cytochrome P4503A EKINS S., MURRAY G.L, BURKE NOORMOHAMED F.H. (CYP3A), 195P M.D, MARCHANT N.M. & GEISSLINGER G. see LOTSCH J. HALLIDAY R.C., JONES B.C., SMITH HAWKSWORTH G.M. Epoxidation, GEISSLINGER G., MENZEL S., D.A. & PARK B.K. Structural diol formation and glutathione WISSEL K. & BRUNE K. requirements for the inhibition of conjugation in rat hepatocytes and Pharmacokinetics of ketoprofen CYP2D6 by imipramine, 194P precision-cut liver slices, 180P enantiomers after different doses of HALLIDAY R.C., JONES B.C., SMITH EKLUNDH T. see KIIVET R.A. the racemate, 73 D.A., KITTERINGHAM N.R. & ELLIS S.W., HAYHURST G_P., GENTILE D.M. & BACK PARK B.K An investigation of the HARLOW J.R., LENNARD MS., D.J. Inhibition of dexamethasone interaction between halofantrine, TUCKER G.T., SIMULA A.P., 6-hydroxylation in human liver CYP2D6 and CY P3A¢4: studies with SMITH G. & WOLF C.R. Catalytic microsomes, 192P human liver microsomes and functions of aspartic acid 301 in GEORGE C.F. see RASHID T.J. heterologous enzyme expression debrisoquine, 4-hydroxylase GEORGIOU P. see COMPTON C. systems, 369 cytochrome P450 (CYP2D6), 178P GERARD N. see PANSERAT S. HARA K. see UEMATSU T. ESLER M. see EISENHOFER G. GERSLINGER G. see LOTSCH J. HARLOW JR. see ELLIS S.W. GESCHER A. see BARCELO S. HARRIS A.M. see BULLIMAN S. FAIRWEATHER D.B., PATAT A., GIBSON J. see STARMER G.A. HARTER K. see BOLDT J. ROSENZWEIG P., CURSON V.H., GIBSON P. see DRAKE J. HAWKINS N., GOLDING J. & © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 606 Index ALSPAC Survey Team. A survey of IND P.W. see HIGHAM M.A. KITTERINGHAM N.R. see HOWARD the administration of drugs to young IND P.W. see SHARAHA A.M. NJ. infants, 79 IND P.W. see SHARARA A.M. KITTERINGHAM N.R., KENNA J.G. HAWKSWORTH G.M. see EKINS S. IREDALE M.J. see SHARARA A.M. & PARK B.K. Detection of HAYHURST G_P. see ELLIS S.W. ISHIZAKI T. see KOBAYASHI K. autoantibodies directed against HAYNER W.G., MOFFAT S. & WEBB IVERSEN S.A., DAVIDSON D. & human hepatic endoplasmic reticulum D.J. An investigation into the direct DAVIDSON C. The acceptability of in sera from patients with halothane- and indirect venoconstrictor effects of resin therapy to patients attending a associated hepatitis, 379 endothelin-1 and big endothelin-1 in hospital lipid clinic, 92 KIVISTO K.T., KROEMER H.K. &' man, 307 EICHELBAUM M. The role of HAYNES W.G. see STRACHAN F-.E. JACKSON P.R. see ROSTAMI- human cytochrome P450 enzymes in HAYNES W.G. see WEBB D.J. HODJEGAN A. the metabolism of anticancer agents: HEESEN M. see BOLDT J. JACKSON P.R. see YEO W.W. implications for drug interactions, 523 HEINZEL G. see DEGNER F.L. JACQZ-AIGRAIN E. see PANSERAT S. KNIGHTS K.M., McLEAN CLF., HEMPELMANN G. see BOLDT J. JAKESZ R. see MADER R.M. TONKIN A.L. & MINERS J.O. HENRY J.A. see MINTON N.A. JANE F. see AZCONA O. Lack of effect of gender and oral HIGGINS R. see COMPTON C. JEANNERET-GROSJEAN A. see contraceptive steroids on the HIGHAM M.A. see SHARAHA A.M. DEMNATIR. pharmacokinetics of (R)-ibuprofen in HIGHAM M.A., SHARARA A.M., JOEL S.P. see THOMPSON PI. humans, 153 MAGEE R.P. & IND P.W. JOHN L. see THOMPSON P.I. KOBAL G. see LOTSCH J. Determination of the minimum dose JONES B. see HYLAND R. KOBAYASHI K., YAMAMOTO T., of lactose drug carrier that can be JONES B.C. see HALLIDAY R.C. CHIBA K., TANI M., ISHIZAKI T. sensed during inhalation, 281 JONES D. see CRAWFORD D. & KUROIWA Y. The effects of HILL J. & BRITTON J. Dose-response JONES P.S see BELL D.R selective serotonin reuptake inhibitors JORG K. see DINGEMANSE J. relationship and time-course of the and their metabolites on JORKASKY D.K. see BULLIMAN S. effect of inhaled magnesium sulphate S-mephenytoin, 4-hydroxylase on airflow in normal and asthmatic activity in human liver microsomes, KAMALIF. see BALL DE. 481 subjects, 539 KAMALI F. see WYNNE H. HILL R.G. see FERRO A. KOSUGE K. see UEMATSU T. KAMALI F., HOWES A., THOMAS HILL S.J. see COOPER J.A. S.H.L. & SNOECK E. The effects of KRASKIEWICZ M. see YEO W.W. HILLAIRE-BUYS D., PEYRIERE H., ranitidine and cimetidine on the KRISHNAMOORTHY R. see LOBJOIE E., BRES J., OSSART M. pharmacokinetics and PANSERAT S. & DESPAUX E. Influence of arterio- pharmacodynamics of nebivol P, 519 KRIVORUK Y. see TATEISHI T. KROEMER HK. see KIVISTO K.T. venous haemofiltration on teicoplanin KANAMARU M. see UEMATSU T. elimination, 95 KANG W. see WANWIMOLRUK S. KUHN RJ. seeOO C.Y. KUROIWA Y. see KOBAYASHI K. HINDMARCH I. see FAIRWEATHER KARBWANG J. see AUPRAYOON P. KVISTO K.T., KROEMER H.LK. & D.B. KAYE C. see COMPTON C. HOFFMAN C. see BERNDT A. KELLY P. see WYNNE H. EICHELBAUM M. Review. The role of human cytochrome P450 enzymes HOFSTATTER E. see MUSCARA M.N. KENNA J.G. see GARDNER LB. in the metabolism of anticancer HOGGARD P.G., VEAL G.J., BARRY KENNA J.G. see KITTERINGHAM agents: implications for drug M.G. & BACK D.J. Zidovudine N.R. interactions, 259 phosphorylation in peripheral blood KHALIL S.K.W. see DUCHARME J. mononuclear cells in vitro: effect of KHAN S. & SKETT P. The effect of LABORDE C. see BANNWARTH B. depleting T4 cells P, 191 DMSO on steroid metabolism in LACARELLE B. see SAMPOL E. HOP W.C.J. see VAN DEN ANKER cultured rat hepatocytes in the LACIMA G. see GRANDE L. JN. presence of hydrocortisone and LANGLEY R.W. see ABDELMAWLA HORN E.H. see COOPER J.A. insulin P, 186 HOROWITZ J.D. see ZHANG Y. KIELY D.G., CARGILL RI. & A.H. LANT A.F. see FEHER M.D. HORTH C.E. see DRAKE J. LIPWORTH B.J. Angiotensin II HOTCHKISS S.A.M. see BECKLEY- blockade attenuates hypoxic LANT A.F. see NOORMOHAMED KARTEY S.A.J. pulmonary vasoconstriction in man, F.H. 505P LAPICQUE F. see BANNWARTH B. HOUSTON J.B. see CARLILE D.J. KIELY D.G., CARGILL RI. & LARSON P. see SCHOORS D.F. HOUSTON J.B. see WITHEROW L.E. LIPWORTH B.J. Cardiopulmonary LEE MLR. see NEWBY D.E. HOUSTON J.B. see WORBOYS P.D. interactions of salbutamol and LEITCH A. see SILKE B. HOWARD N.J., DAVIES C.D., hypoxaemia in healthy young LEITE G. see MUSCARA MLN. ALLOTT R.L., MADDEN S., volunteers, 313 LENNARD L. see ROSTAMI- PIRMOHAMED M., KIELY D.G., CARGILL RI. & HODJEGAN A. KITTERINGHAM N.R. & PARK LIPWORTH B.J. Cardiopulmonary LENNARD M.S. see COLEMAN T. B.K. Species variation in microsomal interactions of salbutamol and LENNARD M.S. see ELLIS S.W. epoxide hydrolase activity, 509P hypoxaemia P, 506 LEONARDI S. see MUSCARA MLN. HOWES A. see KAMALI F. KITVET R.A., LLERENA A., DAHL M., LEONHARDT A. see CAWELLO W. HUMMEL T. see LOTSCH J. ROOTSLANE L., VEGA JS., LIJESEN G.K.S, THEEUWEN L, HUSSEIN Z. see LIPTROT J. EKLUNDHT. & SJOQVIST F. ASSENDELFT W.J.J. & VAN DER HUTCHEON LG. see STRACHAN Patterns of drug treatment of WAL G. The effect of human FE. schizophrenic patients in Estonia, chorionic gonadotropin (HCG) in the HYLAND R., JONES B., LOGAN A., Spain and Sweden, 467 treatment of obesity by means of the MANSFIELD R., MOORE R. & KINGSWOOD C. see DAVIES J.G. Simeons therapy: a criteria-based SMITH D. Production of a human KIRKPATRICK C.T. see DRAKE J. meta-analysis, 237 CYP3A antibody from multiple KITTERINGHAM NR. see LILLEYMAN JS. see ROSTAMI- peptide sequences, 179P HALLIDAY R.C. HODJEGAN A. © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 607 LIM J. see REIDENBERG P. MARSH V.R see MOORE U.J. HOFSTATTER E., LEITE G., LIM P.O. see CLARKSON P.B.M. MARTIN ARIAS L.H., CARVAJAL A., MAGALHAES A.F., LEONARDI S. LIN C. see REIDENBERG P. MARTIN DE DIEGO IL. & DE & DE NUCCIG. Plasma hydroxy- LIPTROT J., MERCER J., HUSSEIN ABAJO F. Letter to the Editor: metronidazole/metronidazole ratio in Z., SEABER E. & POSNER J. The Before and after triazolam:changes in patients with liver disease and in tolerability and pharmacokinetics of the consumption of hypnotics in healthy volunteers, 477 loading and maintenance intravenous Spain, 289 infusions of 619C89 in healthy MARTIN DE DIEGO I. see MARTIN NA-BANGCHANG K. see volunteers, 507P ARIAS L.H. AUPRAYOON P. LIPWORTH B.J. see CARGILL R.I. MARTIN J.F. see RAMSAY B. NAISBITT D.J., WILLIAMS D.P., LIPWORTH B.J. see KIELY D.G. MARTIN U. see RASHID T.J. PIRMOHAMED M., O’NEILL LIPWORTH B.J. see TAN KS. MARTIN-MUNLEY S. see P.M., PIRMOHAMED M., LLERENA A. see KITVET R.A. NOORMOHAMED F.H. O’NEILL P.M. & PARK B.K. LOBJOIE E. see HILLAIRE-BUYS D. MASCORD D.J. see STARMER G.A. Depletion of intracellular glutathione LOGAN A. see HYLAND R. MATAS N., THYGESEN P. & SIM E. in polymorphonuclear leucocytes by LOMAX C.C. see STRACHAN F-.E. Molecular genetics of human antimalarial drugs, 511P LOMELI A.L. see CAWELLO W. arylamine n-acetyltransferase: NAKASHIMA M. see UEMATSU T. LONGMORE J. see FERRO A. physical mapping, 522P NARJES H. see DEGNER F.L. LONGSTRETH J.A. see GUPTA S.K. MATTHIAS M. see BOLDT J. NEIJENS H.J. see WALKER D.K. LOPEZ-JARAMILLO P. see MATTILA M.J. see VANAKOSKI J. NETTER P. see BANNWARTH B. RAMSAY B. McCAPPIN T.R. & DALEY-YATES NEUVONEN PJ. see AHONEN J. LOTSCH J., GERSLINGER G., P.T. The pharmacokinetics and NEWBY D.E., LEE M.R., GRAY AJ. & MOHAMMADIAN P., BRUNE K. pharmacodynamics of BOON N.A. Letter to the Editor: & KOBAL G. Effects of flurbiprofen bisphosphonates in rats with retinoid- Enalapril overdose and the corrective enantiomers on pain-related induced bone resorption, 183P effect of intravenous angiotensin II, chemosomato-sensory evoked McCORMAC P. see HALL M. 103 potentials in human subjects, 339 McDERMOTT B.J. see THAM T.C.K. NICHOLLS M.G. see WOO K:S. LOTSCH J.,. MOHAMMADIAN P., McFARLANE L.C. see TAN K:S. NOMEIR A. see REIDENBERG P. HUMMEL T., FLORIN S., McLEAN C.F. see KNIGHTS K.M. NOORMOHAMED F.H., YOULE BRUNE K., GEISSLINGER G. & McLEAN S. see MILLER RS. M.S., TANG B., MARTIN- KOBAL G. Effects of azapropazone McMANUS P. see BIRKETT D.J. MUNLEY S., GAZZARD B.G. & on pain-related brain activity in McMURRAY J. see CLAPPERTON M. LANT A-F. Foscarnet-induced human subjects, 545 McNAMARA P.J. see OO C.Y. changes in plasma calcium and LYLES G.A. see PINO R. MEEHAN J. see REIDENBERG P. magnesuim in HIV seropositive LYNN F. see COCKCROFT J.R. MEINDERS AE. see BLAUW G.J. patients, 502P MENZEL S. see GEISSLINGER G. NOTARIANNI L.J., BELK D., AIRD MacALLISTER R.J. see DAVIES G. MERCER J. see LIPTROT J. S.A. & BENNETT P.N. An in vitro MacDONALD T.M. see CLARKSON MICHAEL-TITUS A.T., WHELPTON technique for the rapid determination P.B.M. R. & YAQUB Z. Binding of of drug entry into breast milk, 333 MACKIE A.E., VENTRESCA G_P., temoporfin to the lipoprotein NURMINEN S. see ROSTAMI- MOSS J.A. & BYE A. fractions of human serum, 594 HODJEGAN A. Pharmacokinetics of intravenous MICHOUD M.C. see DEMNATI R. NUTT DJ. see COUPLAND N.J. fluticasone propionate in healthy MILLER R.S., PETERSON G.M., subjects, 198P ABBOTT F., MADDOCKS L, O’CALLAGHAN C. see BARRY P.W. MACKLIN BS. see ROBERTS J. PARKER D. & McLEAN S. Plasma O’KANE K.P.J. see STRACHAN F-.E. MACLEAN M. see THOMPSON PI. concentrations of fentanyl with O’NEILL C.J.A. see PURKISS A.G. MADDEN S. see HOWARD N.J. subcutaneous infusion in palliative O’NEILL P.M. see NAISBITT D.J. MADDOCKS I. see MILLER RS. care patients, 553 O’SHEA N. see ROBERTS J. MADDOCKS J.L. see CRAWFORD D. MINERS J.O. see KNIGHTS K.M. OERTEL R. see BERNDT A. MADER R.M., STEGER G.G., MINTO C.F. see BILLARD V. OLDFIELD S., CLARKE S.E. & RIZOVSKI B., DJIAVANMARD MINTON N.A., TURNER J. & HENRY BEEDHAM C. In vitro interaction of M.P., SCHEITHAUER W., JAKESZ J.A. Pharmacodynamic and (E)-5-(2-bromoviny] )uracil with, R. & RAINER H. Stereospecific pharmacokinetic interactions between 5-fluorouracil metabolism in human pharmacokinetics of rac-5- theophylline and propranolol during liver, 189P methyltetrahydrofolic acid in patients dynamic exercise, 521P OLKKOLA K.T. see AHONEN J. with advanced colorectal cancer, 209 MIRANDA E.L. see MUSCARA M.N. OLLIFF C.J. see DAVIES J.G. MAGALHAES A.F. see MUSCARA MOFFAT S. see HAYNER W.G. OO C.Y., KUHN R.J., DESAI N., MLN. MOHAMMADIAN P. see LOTSCH J. WRIGHT C.E. & MCNAMARA MAGEE R.P. see HIGHAM M.A. MOLUNTO P. see AUPRAYOON P. P.J. Pharmacokinetics in lactating MAGGS J.L. see TOMLINSON ES. MOORE R. see HYLAND R. women: prediction of alprazolam MAGGS J.L. see WILLIAMS D. MOORE U.J., MARSH V.R, ASHTON transfer into milk, 231 MAHMUD R., TINGLE M_D., C.H. & SEYMOUR R.A. Effects of OSSART M. see HILLAIRE-BUYS D. CRONIN M.T.D., DEARDEN J.C. peripherally and centrally acting & PARK B.K. The chemical basis of analgesics on somatosensory evoked PAGE K.M. see WIEBKIN P.F. dapsone haemotoxicity, 511P potentials, 111 PANFILOV V., MORRIS A.D., MALLETT C.D. see WIEBKIN P.F. MORRIS A.D. see PANFILOV V. DONNELLY R., SCEMAMA M. & MANSFIELD R. see HYLAND R. MOSS J.A. see MACKIE A.E. REID J.L. The effects of rilmenidine MANT T.G.K. see COCKCROFT J.R. MURA C. see PANSERAT S. and atenolol on mental stress, MARCHANT N.M. see EKINS S. MURRAY GLI. see EKINS S. dynamic exercise and autonomic MARGOLSKEE D. see SCHOORS MUSCARA M.N., PEDRAZZOLI Jr J., function in mild to moderate DF. MIRANDA E.L., FERRAZ J.G., hypertension, 563 © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 608 Index PANSERAT S., MURA C., GERARD the absolute bioavailability of A.E., PHILIPP TH. & BRODDE N., VINCENT-VIRY M., GALTEAU nifedipine, 51 O.-E. Influence of adrenergic and M.M., JACQZ-AIGRAIN E. & REID J.L. see PANFILOV V. mucarinic receptor blockade on the KRISHNAMOORTHY R. An REIDENBERG P., GLUE P., cardiovascular in vivo effects of unequal cross-over event within the BANFIELD C., COLUCCI R., exogenously administered and CYP2D gene cluster generates a MEEHAN J., REY E., endogenously released noradrenaline chimeric CYP2D7/CYP2D6 gene RADWANSKI E., NOMEIR A., LIM in humans, 504P which is associated with the poor J., LIN C., GUILLAUME M. & SCHEITHAUER W. see MADER R.M. metabolizer phenotype, 361 AFFRIME M.B. Pharmacokinetic SCHMITT M. see DINGEMANSE J. PARK B.K. see GILL HJ. interaction studies between felbamate SCHOEMAKER R.C. see VAN DEN PARK B.K. see HALLIDAY R.C. and vigabatrin, 157 ANKER JN. PARK B.K. see HOWARD N.J. REISS T. see SCHOORS DF. SCHOORS D.F. see DE SMET M. PARK B.K. see KITTERINGHAM N.R. RENWICK A.G. see RASHID T.J. SCHOORS D.F., DE SMET M., REISS PARK B.K. see MAHMUD R. RENWICK A.G. see ROBERTS J. T., MARGOLSKEE D., CHENG H., PARK B.K. see NAISBITT D.J. RENWICK A.G. see SOWUNMI A. LARSON P., AMIN R. & SOMERS PARK B.K. see TOMLINSON ES. REVELEY M.A. see BURKE J.G. G. Single dose pharmacokinetics, PARK B.K. see WILLIAMS D. REY E. see REIDENBERG P. safety and tolerability of MK-0476, a PARKER D. see MILLER R:S. RICHTER K. see BERNDT A. new leukotriene D4-receptor PATAT A. see FAIRWEATHER D.B. RIDDELL J.G. see SILKE B. antagonist, in healthy volunteers, 277 PATTERSON A. see BARHAM H.M. RIDDELL J.G. see THAM T.C.K. SCHROETER V. see DE MEY C. PEDRAZZOLI Jr J. see MUSCARA RITCHIE R.H. see ZHANG Y. SCHWEER H. see CAWELLO W. M.N. RITTER J.M. see COCKCROFT J.R. SEABER E. see LIPTROT J. PEHOURCQ F. see BANNWARTH B. RIZOVSKI B. see MADER R.M. SEDEK G. see DINGEMANSE J. PEREZ A. see GRANDE L. ROASALKI S.B. see FRASER A.G. SEPPALA T. see VANAKOSKI J. PETERSON D. see PURKISS A.G. ROBERTS D. see DOCKENS R.C. SEYBERTH H.W. see CAWELLO W. PETERSON G.M. see MILLER RS. ROBERTS J., WALLER D.G., O'SHEA SEYMOUR R.A. see MOORE U.J. PEYRIERE H. see HILLAIRE-BUYS N., MACKLIN B.S. & RENWICK SHAFER S.L. see BILLARD V. D. AG. The effect of selegiline on the SHANKS R.G. see THAM T.C.K. PHILIPP TH. see SCHAFERS RF. peripheral pharmacokinetics of SHARAHA A.M., HIGHAM M.A., PHILLIPS G.J. see DAVIES J.G. levodopa in young volunteers, 404 SPANEVELLO A. & IND P.W. PINO R. & LYLES G.A. Toxicity of RODGERS E.H. see WILSON Y. Effects of intradermal injections of allylamine and acrolein towards ROLL S. see DE MEY C. atrial natriuretic peptide, 283 human cultured endothelial cells: ROOTSLANE L. see KIIVET R.A. SHARARA A.M. see HIGHAM M.A. involvement of semicarbazide- ROSENZWEIG P., CAPLAIN H., SHARARA A.M., HIGHAM M.A., sensitive amine oxidase, 187P CHAUFOUR S., ULLIAC N., IREDALE M.J. & IND P.W. PIRMOHAMED M. see HOWARD CABANIS M.J. & THEBAULT Intradermal actions of hypertonic N.J. J.J. Comparative wheal and flare saline involve neural and vascular PIRMOHAMED M. see NAISBITT study of mizolastine terfenadine, mechanisms, 98 DJ. cetirizine, loratadine and placebo in SHENFIELD G.M., STRINGER RSS. & PIRMOHAMED M. see WILLIAMS D healthy volunteers, 459 ATKIN P.A. Can we improve POLLER U. see SCHAFERS RF. ROSENZWEIG P. see prescribers’ knowledge of their elderly POSNER J. see LIPTROT J. FAIRWEATHER D.B. patients’ medications? 512P POUNDER RE. see FRASER A.G. ROSTAMI-HODJEGAN A., SHUKLA U.A. see BARBHATYA R.H. PRINCE L.R. see WIEBKIN P.F. LENNARD L. & LILLEYMAN JS. SIEGMUND W. see BERNDT A. PURKISS A.G., CHARLETT A., The accumulation of mercaptopurine SILKE B., THOMPSON A., LEITCH WRIGHT D.J., CHING D., metabolites in age fractionated red A. & RIDDELL J.G. A placebo PETERSON D., O’NEILL C.J.A., blood cells, 217 controlled comparison of the effects of DOBBS S.M. & DOBBS ROSTAMI-HODJEGAN A., metoprolol and celiprolol on echo- R.J. Immunological status, with NURMINEN S., JACKSON P.R. & Doppler measurements of respect to IgG, IgA and IgM, in TUCKER G.T. Caffeine urinary cardiovascular function in normal sufferers from idiopathic metabolite ratios as markers of volunteers, 37 parkinsonism, their spouses and CYP1A2 activity: specificity and SIM E. see MATAS N. siblings, 513P sensitivity, 508P SIMMS J.P. see FEHER M.D. PUSSARD E. see DURANTEAU J. ROSTAMI-HODJEGAN A., SIMON G. see GARCIA-RODRIGUEZ NURMINEN S., JACKSON P.R. & L.A. RADOMSKI M. see RAMSAY B. TUCKER G.T. Caffeine urinary SIMONS M. see BLAUW G.J. RADWANSKIE. see REIDENBERG P. metabolite ratios as markers of SIMULA A_P. see ELLIS S.W. RAINER H. see MADER R.M. CYP1A2 activity: simulation of SJOQVIST F. see KITVET R.A. RAJAONARISON J.F. see SAMPOL E. population distributions, 509P SKETT P. see AL-SHIBANI N. RAMSAY B., RADOMSKI M., de RUBIN P.C. see COOPER J.A. SKETT P. see KHAN S. BELDER A., MARTIN JF. & SKWARSKI K. see WEBB D.J. LOPEZ-JARAMILLO P. Systemic SAMPOL E., LACARELLE B., SLEVIN MLL. see THOMPSON PI. effects of S-nitroso-glutathione in the RAJAONARISON J.F., CATALIN SMITH D. see HYLAND R. human following intravenous J. & DURAND A. Comparative SMITH D.A see WALKER D.K. infusion, 101 effects of antifungal agents on SMITH D.A. see HALLIDAY R.C. RAMSAY L.E. see YEO W.W. zidovudine glucuronidation by SMITH G. see ELLIS S.W. RAPOPORT D. see DOCKENS R.C. human liver microsomes, 83 SNOECK E. see KAMALI F. RASHID T.J. see SOWUNMI A. SCEMAMA M. see PANFILOV V. SOMERS G. see SCHOORS D.F. RASHID T.J., MARTIN U., CLARKE SCHAEVERBEKE T. see SOMERVILLE D.T. see STRACHAN H., WALLER D.G., RENWICK A.G. BANNWARTH B. FE. & GEORGE C.F. Factors affecting SCHAFERS R.F., POLLER U., DAUL SOWUNMIA., RASHID T.J., © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Index 609 AKINYINKA 0.0. & RENWICK BACK D.J. & PARK B.K. WALLEY T. & DAVEY P. Meeting A.G. Ethnic differences in nifedipine Dexamethasone metabolism by Report: Pharmacoeconomics: a kinetics: comparisons between human liver in vitro: metabolite challenge for clinical pharmacologists, Nigerians, Caucasians and South identification, 191P 199 Asians, 489 TONKIN A.L. see KNIGHTS K.M. WANWIMOLRUK S., KANG W., SPANEVELLO A. see SHARAHA A.M. TORRENT J. see AZCONA O. COVILLE P-F., SPENCE J.D. see BAILEY D.G. TRAN L.T. see BAILEY D.G. VIRIYAYUDHAKORN S. & STARMER G.A., GIBSON J. & TU T. see GUPTA S.K. THITIARCHAKUL S. Marked MASCORD D.J. Caffeine and the TUCKER G.T. see COLEMAN T. enhancement by rifampicin and lack development of fatigue in a prolonged TUCKER G.T. see ELLIS S.W. of effect of isoniazid on the driving related task, 516P TUCKER GT. see ROSTAMI- elimination of quinine in man, 87 STEGER G.G. see MADER R.M. HODJEGAN A. WANWIMOLRUK S., THOU MLR. & STENING P. see GARDNER LB. TUERSLEY M.D. see DONAVAN WOODS D.J. Evidence for the STEVENSON P. see COCKCROFT AJ.G. polymorphic oxidation of J.R. TURCK D. see DEGNER F.L. debrisoquine in a Khmer STICKNEY J.L. see BILLARD V. TURNER J. see MINTON N.A. (Cambodian) population, 166 STRACHAN F.E., HAYNES W.G., WEBB D.J. see HAYNER W.G. HUTCHEON L.G., LOMAX C.C., UCHIYAMA N. see UEMATSU T. WEBB D.J. see STRACHAN F.E. O’KANE K.P.J., SOMERVILLE UEMATSU T., KANAMARU M., WEBB D.J., FERRO C.J., HAYNES D.T. & WEBB D.J. An investigation KOSUGE K., HARA K., W.G., SKWARSKI K. & WYLD P. into the development of nitrate UCHIYAMA N., TAKENAGA N., Vasodilator effects of the ETA/B tolerance in human forearm resistance TANAKA W., FRIEDMAN BSS. & receptor antagonist, TAK -044, in and capacitance vessels, 504P NAKASHIMA M. Pharmacokinetic humans, 503P STRATFORD LJ. see BARHAM H.M. and pharmacodynamic analysis of a WEDZICHA J.A. see THOMPSON P.I. STREET M. see DAVIES J.G. novel leukotriene biosynthesis WESTENDORP R.G.J. see BLAUW STRINGER R:S. see SHENFIELD inhibitor, MK-0591 in healthy GJ. G.M. volunteers, 59 WHELPTON R. see MICHAEL-TITUS SUKONTASON K. see AUPRAYOON ULLIAC N. see ROSENZWEIG P. AT. P. UPWARD J. see COMPTON C. WHITTINGHAM T. see WYNNE H. SZABADI E. see ABDELMAWLA A.H. WIEBKIN P-.F., PAGE K.M., PRINCE SZAWLOSKI P. see CRAWFORD D. VALLANCE P. see BHAGAT K. L.R., GUNRAJ P.E. & MALLETT VALLANCE P. see DAVIES G. C.D. A high-sensitivity assay for the TAKENAGA N. see UEMATSU T. VAN BRUMMELEN P. see determination of RP 73401 in human TAN K.S., GROVE A., CARGILL R.L, DINGEMANSE J. plasma using h.p.l.c with on-line McFARLANE L.C. & LIPWORTH VAN DEN ANKER J.N., HOP W.C.J., fluorescence detection, 197P B.J. Effects of inhaled fluticasone SCHOEMAKER R.C. & VAN DER WILLIAMS A.J. see DONAVAN A.J.G. HEIJDEN B.J. Ceftazidime WILLIAMS D, MAGGS J.L., propionate and oral prednisolone on pharmacokinetics in preterm infants: PIRMOHAMED M. & PARK B.K. lymphocyte B2-adrenoceptor function effect of postnatal age and postnatal Bioactivation of clozapine in vitro and in asthmatic patients, 506P TANAKA W. see UEMATSU T. exposure to indomethacin, 439 in vivo: implications for drug-induced VAN DER HEIJDEN B.J. see VAN agranulocytosis, 182P TANG B. see NOORMOHAMED F.H. DEN ANKER J.LN. WILLIAMS D.P. see NAISBITT D.J. TANI M. see KOBAYASHI K. VAN DER HEIJDEN B.J. see WALKER WILSON Y, RODGERS E.H. & TATEISHI T., GRAHAM S.G., D.K. GRANT M.H. Ethacrynic acid KRIVORUK Y. & WOOD VAN DER WAL G. see LIJESEN G.K.S modulates the in vitro cytotoxicity of A.J.J. Letter to the Editor: VANAKOSKI J., MATTILA M.J. & mitoxantrone in MCF 7 human Omeprazole does not affect measured SEPPALA T. Grapefruit juice does breast cancer cells, 190P CYP3A4 activity using the not interact with midazolam in man, WISSEL K. see GEISSLINGER G. erythromycin breath test, 411 520P WITHEROW L.E., GIFFORD L.A. & TESSMAN J.W. see BILLARD V. VEAL G.J. see HOGGARD P.G. HOUSTON J.B. Metabolism and THAM T.C.K., GUY S., McCDERMOTT VEGA JS. see KIIVET R.A. covalent binding of furazolidone in B.J., SHANKS R.G. & RIDDELL VENTRESCA G.P. see MACKIE A.E. vitro in pig liver and muscle fractions, J.G. The dose dependency of the « VERBESSELT R. see DE SMET M. 187P and B-adrenoceptor antagonist VERE D.W. Actions of terfenadine and WOLF C.R. see ELLIS S.W. activity of carvedilol in man, 19 cimetidine on histamine wheal WOO KS. & NICHOLLS M.G. High THEBAULT J.J. see ROSENZWEIG P. formation, 557 prevalence of persistent cough with THEEUWEN |. see LIJESEN G.K.S VEYSSIER-BELOT C. see AZIZI M. angiotensin converting enzyme THITIARCHAKUL S. see VIERKANT A. see BERNDT A. inhibitors in Chinese, 141 WANWIMOLRUK S. VINCENT-VIRY M. see PANSERAT S. WOOD A.J.J. see TATEISHI T. THOMAS S.H.L. see KAMALI F. VIRIYAYUDHAKORN S. see WOODS D.J. see WANWIMOLRUK S. THOMPSON A. see SILKE B. WANWIMOLRUK S. WORBOYS P.D., BRADBURY A. & THOMPSON P.L., JOEL S.P., JOHN L., HOUSTON J.B. A comparison of the WEDZICHA J.A., MACLEAN M. & WAINER I.W. see DUCHARME J. kinetics of caffeine and phenytoin SLEVIN MLL. Respiratory depression WALKER D.K., VAN DER HEIJDEN metabolism in precision cut liver following morphine and morphine-6- B.J., SMITH D.A, NEIJENS H.J. & slices and freshly isolated hepatocytes, glucuronide in normal subjects, 145 DE GROOT R. Differentiation of 188P THOU MLR. see WANWIMOLRUK S. compounds which bind to P450 WRIGHT CLE. see OO C.Y. THYGESEN P. see MATAS N. isozymers CYP2C9 and CYP3A4 by WRIGHT D.J. see PURKISS A.G. TINGLE M_D. see GILL HJ. physicochemical properties, 178 P WRITER D.J. see BULLIMAN S. TINGLE M.D. see MAHMUD R. WALLER DG. see RASHID T.J. WYLD P. see WEBB D.J. TOMLINSON E.S., MAGGS J.L., WALLER D.G. see ROBERTS J. WYNNE H., COPE L., KELLY P., © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 610 Index WHITTINGHAM T., EDWARDS C. YEO W.W., CHADWICK I.G., ZARIFFA N. see BULLIMAN S. & KAMALIF. The influence of age, KRASKIEWICZ M., JACKSON ZAYAS J.M. see GRANDE L. liver size and enantiomer P.R. & RAMSAY L.E. Resolution of ZHANG Y., RITCHIE R.H. & concentrations on warfarin ACE inhibitor cough: changes in HOROWITZ J.D. Postextrasystolic requirements, 203 subjective cough and responses to potentiation in patients with inhaled capsaicin, intradermal ischaemic heart disease: influence of bradykinin and substance-P, 423 inotropic agents, 25 YAMAMOTO T. see KOBAYASHI K. YOULE MSS. see NOORMOHAMED ZOMORODI K. see CARLILE D.J. YAQUB Z. see MICHAEL-TITUS A.T. F.H. ZURCHER G. see DINGEMANSE J. © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 603-610 Br J Clin Pharmacol 1995; 40: 611-613 SUBJECT INDEX This index is compiled from the keywords (P = Proceedings) Absorption, 387 Caffeine, 188P, 393, SO8P, SO9P, 516P Debrisoquine, 166 ACE inhibitor, 423 Calcium, 502P Desipramine, 263, 445 Acetyltransferase, 193P Cancer, 553 Dexamethasone, 181P, 192P Acrolein, 187P Capsaicin, 423 Dexamethasone metabolism, 191P Adrenal medulla, 263 Captopril, 31, 141 Diadenosine phosphates, 170 Adrenaline, 263, 453 Cardiovascular reflexes, 431 Diastole, 299 Adrenergic receptor blockade, 504P Carvedilol, 19 Diazepam, 181P Adverse drug reactions, 173 Cat, 183P Diet, 237 Age, 203 Caucasians, 489 Digoxin, 571 Agranulocytosis, 182P Cefpirome, 521P Dimethylnitrosamine, 193P Agreement, 291 Ceftazidime, 439 Dinamap, 291 Airway resistance, 539 Celiprolol, 37 Diol formation, 180P Alcohol, 393 Central nervous system, 266, 393 Dorsal hand vein, 443 Allylamine, 187P Cephalosporin, 521P Dose dependency, 19 Alpha-adrenoceptor antagonism, 19 Cerebral ischaemia, 507P Dose proportional pharmacokinetics, 273 Alpha,-adrenoceptors, 443 CGS 21680, 43 Driving-related task, 516P Alprazolam, 231 Chemiluminescence, 31 Drug administration-inhalation, 76 Analgesics, 111, 339, 545 Chemo-somatosensory, 339 Drug delivery devices, 76 Angiotensin II, 591 Chemo-somatosensory event-related Drug interaction, 87, 161, 598 Angiotensin II blockade, 505P potentials, 545 Drug subsidy, 407 Angiotensin converting enzyme Chicken pox, 513P Drug therapy, 199 inhibitors, 141, 415 Childhood leukaemia, 217 Drug use, 79, 407, 467 Angiotensin receptors, 591 Children, 79 DuP, 753, 571 Anticancer agents, 523 Chinese, 141 Dynamic exercise, 563 Antidepressants, 119 Chiral inversion, 153 Antifungal agents, 83 Cholestyramine, 92 Echo-Doppler, 37 Antimalarial drugs, 511P Chronic liver disease, 494 Economics, 199 Antimycotics, 270 Cimetidine, 161, 519P, 557 (E)-5-(2-bromoviny] )uracil, 189P Appetite, 237 Circulation, 415 Elderly, 325, 512P Asians, 166 Cirrhosis, 477 Electrostatic charge, 76 Aspartic acid, 178P Citalopram, 481 Enalapril, 141 Aspirin, 111 Clozapine, 182 P Enalaprilat, 415 Asthma, 76, 539, 506P, 518P Codeine, 111 Enantiomers, 127, 339 Atenolol, 563 Cognitive function, 119 Enantioselective pharmacokinetics, 67 AT, angiotensin II receptors, 571 Cohort study, 79 Endothelium, 307 Atrial natriuretic peptide, 283 Colestipol, 92 Endotoxin, 502P A>, adenosine receptor, 43 Colorectal cancer, 209 Enzyme induction, 87 Autoantibodies, 379 Comet assay, 193P Epoxide hydrolase, 180P Autonomic function, 563 COMT inhibition, 253 Epoxide hydrolase, 509P Concentration-effect relationship, 253 Erythrocytes, 253 B-acetyl-digoxin, 486 Continuous arterio-venous Erythromycin breath test, 411 B-adrenoceptor antagonist, 19, 25, 313, haemofiltration, 95 ET,, g receptor antagonist, 503P 453, 519P Coronary vasoconstriction, 245 Ethacrynic acid, 190P B-adrenoceptor blockade, 37 Corticosteroids, 76 Ethanol, 387 B-adrenergic receptors, 453 Cough, 141 Ethnic differences, 51, 498 BRL 49653C, 517P Coumarin, 196P Evaluation, 199 BRL 55834, 518P Critically ill, 415 Event-related potentials, 339 B,-adrenoceptor, 506P CYP1A2, 193, 508P, SO9P Exercise, 37, 514P, 521P Bias, 291 CYP3A, 51, 179P, 195P Bioavailability, 51 CYP3A enzymes, 489 Fat distribution, 237 Bioflavonoids, 51 CYP3A4, 369, 135, 178P Fatigue, 516P Bisphosphonates, 183P CYP3A4 activity, 411 Felbamate, 157 Bladder carcinogens, 521P CYP2C9, 178P Felodipine, 135 Blood pressure, 223, 291, 307, 307, 391 CYP2D, 189P Fentanyl, 553 Blood pressure monitoring, 223 CYP2D allele, 361 Finapres, 291 Blood-milk, 231 CYP2D6, 369, 178P, 194P Finger pulse, 291 Bradykinin, 423 Cystic fibrosis, 319 5-fluorouracil, 189P Breast cancer, 194 Cytochrome P-450, 135, 509P, 510P, 523, 5-hydroxytryptamine, 245 Breast cancer cells, 190P 531 5-lipoxygenase inhibitor, 59 Breast feeding, 231 Cytochrome P450-debrisoquine, 5-methyltetrahydrofolic acid, 209 Breast milk, 333 4-hydroxylase, 361 Flare, 98, 283, 459 Bronchodilator, 539 Fluoxetine paroxetine, 481 Budesonide, 76 DMSO, 186P Flurbiprofen, 339 Bufuralol, 189P Dapsone, 510P, 511P, 531 Fluticasone propionate, 198P, 506 © 1995 Blackwell Science Ltd 611 612 Index Food, 387, 517P Leukotriene B4, 59 Parkinson’s disease, 253 Food-drug interaction, 135 Levodopa, 253, 401, 404 P450 isoenzymes, 178P Forearm blood flow, 591 Lignocaine, 98 P4502E1, 193P Foscarnet, 502P Litoxetine, 119 P-Glycoprotein, 523 Furazolidine, 187P Liver microsomes, 83 Pharmaco-epidemiology, 79 Liver size, 203 Pharmacodynamics, 37, 145, 253, 325, Gastrointestinal sphincter, 401 Losartan, 431, 571 519P, 521P Gastro-oesophageal sphincter, 401 Low molecular weight heparins, 577 Pharmacoepidemiology, 407 Gender, 153, 325 Lower body negative pressure, 431 Pharmacogenetics, 166 Genetic polymorphism, 361 Lung cancer, 194P Pharmacokinetic interaction, 486, 521P Glucuronidation, 83 Pharmacokinetics, 59, 87, 95, 119, 127, Glutathione, 180, 511P Magnesium, 502P, 539 153, 209, 231, 253, 277, 319, 325, 347, Glycogen phosphorylase, 185P Manometry, 401 404, 439, 477, 494, 507P, 517P, 518P, Grapefruit, 135 Market uptake, 407 553, 577 Grapefruit juice, 51, 520P Meloxicam, 486 Pharmacological effects, 319 Guanamines, 185 P Mental stress, 563 Phenytoin, 183P Mercaptopurine, 217 Phenytoin metabolism, 188P Haemodialysis, 521P Meta-analysis, 237 Photodynamic therapy, 594 Haemodynamics, 415 Metabolism, 477, 531 Plasma and CSF concentrations, 266 Haemofiltration, 95, 521P Metabolites, 273, 481 Plasma concentrations, 553 Haemotoxicity, 51iP Methyleugenol, 196P Platelet aggregation, 101 Halofantrine, 195P, 369 Metoprolol, 37, 189P PMA, 31 Halothane, 379 Metronidazole, 477 Poor metabolizer, 361 HCG, 237 Microcirculation, 415 Postextrasystolic potentiation, 25 Healthy volunteers, 119, 431, 459, 577 Microsomes, 369 Postnatal age, 439 Heart failure, 141 Midazolam, 270, 520P Potassium channel activator, 518P Hepatitis, 379 Milrinone, 25 PPAR RNAs, 184P Histamine, 557 Mitoxantrone P, 190 Prediction model, 231 H, antihistamine, 459 MK-0476, 277 Prednisolone, 506 HIV infection, 107, 502 MK-0591, 59 Prescribers’ knowledge, 512P Human arylamine N-acetyltransferase, MK-954, 571 Presynaptic sodium channel inhibitors, 522P Modelling, 253 507P Human chorionic gonadotropin, 237 Monoamine transporter, 263 Preterm infants, 439 Human coronary artery, 245 Morphine, 145, 517P Proguanil, 166 Human liver microsomes, 192P Morphine-6-glucuronide, 145 Propranolol, 521P Human platelets, 43 MPG, 31 Prostaglandin E1, 273 Human serum lipo-proteins, 594 MST continus, 517P Protein binding, 594 Human skin, 283, 557 Muscarinic receptor blockade, 504P Protirelin, 223 Hydrocortisone, 186P Psychomotor performance, 119 Hydroxychloroquine, 127 NECA, 43 Psychomotor tests, 563 Hydroxylamine, 531 Natriuretic peptides, 11, 585 Psychophysiological measurements, 393 Hyperlipidaemia, 92 Nebivol, 519P Pulmonary circulation, 11, 313, 585 Hypertension, 141, 563 Nebuliser, 313 Pulmonary vasoconstriction, 505P Hypertonic saline, 98 Nefazodone, 161, 598 Hypoxaemia, 11, 313, S06P, 585 Nephrotoxicity, 67 Quinine, 87 Hypoxia, 453 Neuroleptics, 467 Ranitidene, 519P Neuronal uptake, 263 Ibuprofen, 67, 266 RB90740, 181P Nifedipine, 51, 489 Idiopathic parkinsonism, 513P Red cell metabolism, 217 Nigerians, 489 Imipramine, 194P 9-methoxypsoralen, 347 Regional blood flows, 431 Immunological status, 513P Renal haemodynamics, 67 Nitrate tolerance, 504P Immunosuppressants, 507P Nitric oxide, 101, 299 Renin-angiotensin system, 11 In vitro metabolism, 369 Respiratory depression, 145 Non-prescription drugs, 79 In vitro technique, 333 Non-steroidal anti-inflammatory drugs, Retinoid-induced bone resorption P, 183 In-patients, 467 266 (R)-ibuprofen, 153 Indomethacin, 439 Rifampicin, 87 Noradrenaline, 263, 453, 504P Infusion, 273 Right ventricular function, 415 Noradrenaline methoxamine, 443 Inhalation, 281 Rilmenidine, 563 Inhibition, 531 RP, 73401, 197 Insulin, 186P Obesity, 237 Interaction, 270, 393 Oesophagus, 401 Salbutamol, 319, 506P Omeprazole, 411 Intravenous, 347 Saralasin, 505P Isoniazid, 87 Oral contraceptive steroids, 153 Schistosomiasis, 477 Isoprenaline, 291 Oramorph SR, 517P Schizophrenia, 467, 515P Organ perfusion, 415 Selegiline, 401, 404 Khmers, 166 Oscillometry, 291 Semicarbazide-senstive amine oxidase, Korotkoff sounds, 291 Oxidation polymorphism, 166 187P Oxygen uptake, 31 Setraline, 481 LTD4-receptor antagonist, 277 Simeons, 237 Lactose, 281 Pancopride, 401 Sino atrial node modulator P, 514 Left ventricle, 299 Paracetamol, 79, 111 Slow-release formulation, 135 © 1995 Blackwell Science Ltd British Journal of Clinical Pharmacology 40, 611-613

See more

The list of books you might like

Upgrade Premium
Most books are stored in the elastic cloud where traffic is expensive. For this reason, we have a limit on daily download.
DMCA & Copyright: Dear all, most of the website is community built, users are uploading hundred of books everyday, which makes really hard for us to identify copyrighted material, please contact us if you want any material removed.
Copyright @ PDFdrive.to, 2022 | We love our users